# Patent

## Title
α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors

## Abstract

Certain Alpha- and Beta-amino acid hydroxyethylamino sulfamic acid derivatives represented by the following formula are useful as retroviral protease inhibitors:

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of prior filed application 10/178,956, filed Jun. 25, 2002, now U.S. Pat. No. 7,037,941, which is a divisional of application 09/633,063, filed Aug. 4, 2000, now U.S. Pat. No. 6,444,678, which is a divisional of application 08/379,545 filed Feb. 2, 1995, now U.S. Pat. 6,156,768, which is a 371 of PCT/L1593/10552 filed Oct. 29, 1993, which is a continuation of 07/968,730 filed Oct. 30, 1992 now abandoned.


BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to retroviral protease inhibitors and, more particularly, relates to novel compounds and a composition and method for inhibiting retroviral proteases. This invention, in particular, relates to sulfamic acid derivatives of hydroxyethylamine protease inhibitor compounds, a composition and method for inhibiting retroviral proteases such as human immunodeficiency virus (HIV) protease and for treating a retroviral infection, e.g., an HIV infection. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
2. Related Art
During the replication cycle of recroviruses, gag and gag-pol gene products are translated as proteins. These proteins are subsequently processed by a virally encoded protease (or proteinase) to yield viral enzymes and structural proteins of the virus core. Most commonly, the gag precursor proteins are processed into the core proteins and the pol precursor proteins are processed into the viral enzymes, e.g., reverse transcriptase and retroviral protease. It has been shown that correct processing of the precursor proteins by the retoviral protease is necessary for assembly of infectious virons. For example, it has been shown that frameshift mutations in the protease region of the pol gene of HIV prevents processing of the gag precursor protein. It has also been shown though site-directed mutagenesis of an aspartic acid residue in the HIV protease that processing of the gag precursor protein is prevented. Thus, attempts have been made to inhibit viral replication by inhibiting the action of retroviral proteases.
Retroviral protease inhibition may involve a transition-state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds to the enzyme in competition with the gag and gag-pol proteins to thereby inhibit replication of structural proteins and, more importantly, the retroviral protease itself. In this manner, retroviral replication proteases can be effectively inhibited.
Several classes of compounds have been proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such compounds include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP O 346 847; EP O 342,541; Roberts et al, “Rational Design of Peptide-Based Proteinase Inhibitors, “Science, 248, 358 (1990); and Erickson et al,” Design Activity, and 2.8 Å Crystal Structure of a C2 Symmetric Inhibitor Complexed to HIV-1 Protease,” Science, 249, 527 (1990).
Several classes of compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. Pat. No. 4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115 and U.S. Ser. No. H725. Of these, G.B. 2,200,115, G.B. 2,209,752, EP O 264,795, U.S. Ser. No. H725 and U.S. Pat. No. 4,599,198 disclose urea-containing hydroxyethylamine renin inhibitors. G.B. 2,200,115 also discloses sulfamic acid-containing hydroxyethylamine renin inhibitors, and EP 0264 795 discloses certain sulfamic acid-containing hydroxyethlamine renin inhibitors. However, it is known that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally cannot be predicted to be effective HIV protease inhibitors.
BRIEF DESCRIPTION OF THE INVENTION
The present invention is directed to virus inhibiting compounds and compositions. More particularly, the present invention is directed to retroviral protease inhibiting compounds and compositions, to a method of inhibiting retroviral proteases, to processes for preparing the compounds and to intermediates useful in such processes. The subject compounds are characterized as sulfamic acid derivatives of hydroxyethylamine inhibitor compounds.


DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided a retroviral protease inhibiting compound of the formula:




or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:

    R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, alkoxycarbonyl, aryloxyalkyl, heteroaryloxyalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkvalkyl radicals, or wherein said aminocarbonyl and aminoalkanoyl radicals are disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen, radicals as defined for R3 or R′′SO2— wherein R′′ represents radicals as defined for R3; or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radicals;
    R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(SC5H5), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-alkyl serine, aspartic acid, beta-cyanoalanine and valine side chains;
    R1′ and R1′′ independently represent hydrogen and radicals as defined for R1, or one of R1′ and R1′′, together with R1 and the carbon atoms to which R1, R1′ and R1′′ are attached, represent a cycloalkyl radical;
    R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radials, —NO2, —CN, —CF3, —OR9 and —SR9, wherein R9 represents hydrogen and alkyl radicals;
    R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone and sulfoxide derivatives thereof;
    R4 and R5 independently represent hydrogen and radicals as defined by R3 or together with a nitrogen atom to which they are bonded form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and aryl radicals and the sulfone and sulfoxide derivatives thereof;
    R6 represents hydrogen and alkyl radicals;
    x represents 1 or 2;
    t represents either 0, 1 or 2; and
    Y represents O, S and NR15 wherein R15 represents hydrogen and radicals as defined for R3.


A family of compounds of particular interest within Formula I are compounds embraced by Formula II:




wherein:

    R represents hydrogen, alkyl, alkenyl, cycloalkyl, hydroxyalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, alkoxycarbonyl, alkoxyalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical or aminocarbonyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2 (SC6H5), —C(CH3)2(S[O]CH3)—C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-methyl serine, aspartic acid, beta-cyanoalanine and valine side chains;
    R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, —NO2, —C≡N, CF3, —OR9, —SR9, wherein R9 represents hydrogen and alkyl radicals;
    R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide derivatives thereof;
    R4 and R5 independently represent hydrogen and radicals as defined by R3, or together with the nitrogen atom to which they are bonded represent heterocycloalkyl and heteroaryl radicals.


A more preferred family of compounds within Formula II consists of compounds wherein:

    R represents hydrogen, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminocarbonyl or aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents CH2C(O)NHCH3, C(CH3)2 (SCH3), C(CH3)2(S[O]CH3), C(CH3)2(S[O]2CH3), alkyl, alkenyl and alkynyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteine and methionine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine;
    R2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula —OR9 and —SR9 wherein R9 represents alkyl radicals; and
    R3 represents alkyl, haloalkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl and hereroaralkyl radicals; and
    R4 and R5 independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals, or R4 and R5 together with the nitrogen atom to which they are bonded from a heterocycloalkyl or heteroaryl radical.


Of highest interest are compounds within Formula II wherein

    R represents alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents CH2C(O)NHCH3, C(CH3)2(SCH3), C(CH3)2(S[O]CH3), C(CH3)2(S[O]2CH3), methyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, allo-iso-leucine, iso-leucine, and beta-cyano alanine side chains;
    R2 represents CH3SCH2CH2—, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;
    R3 represents propyl, isoamyl, n-butyl, isobutyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl radicals; and
    R4 and R5 independently represent hydrogen and methyl, ethyl, i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl and phenyl radicals, or together with the nitrogen atom to which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or N′-alkylpiperazinyl radical.


Another family of compounds of particular interest within Formula I are compounds embraced by Formula III:




wherein:

    R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxcarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl; heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;
    R1′ and R1′′ independently represent hydrogen and radicals as defined for R1, or one of R1′ and R1′′, together with R1 and the carbon atoms to which R1, R1′ and R1′′ are attached, represent a cycloalkyl radical;
    R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radials, —NO2, —C≡N, CF3, —OR9 and —SR9, wherein R9 represents hydrogen and alkyl radicals;
    R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, hereroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide derivatives thereof;
    R4 and R5 independently represent hydrogen and radicals as defined by R3, or together with the nitrogen atom to which they are bonded represent heterocycloalkyl and heteroaryl radicals.


A more preferred family of compounds within Formula III consists of compounds wherein

    R represents an arylalkanoyl, heteroaroyl, aryloxyalkanoyl, aryloxycarbonyl, alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, or disubstituted aminoalkanoyl, or mono-or dialkylaminocarbonyl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent a heterocycloalkyl or heteroaryl radical;
    R1, R1′ and R1′′ independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms, alkenyl, alkynyl, aralkyl radicals, and radicals represented by the formula —CH2C(O)R′′ or —C(O)R′′ wherein R′′ represents R38, —NR38R39 and OR3S wherein R38 and R39 independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms;
    R2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula —OR9 and —SR9 wherein R9 represents hydrogen and alkyl radicals; and
    R3 represents alkyl, haloalkyl, alkenyl, alkynyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl radicals; and
    R4 and R5 independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals, or R4 and R5 together with the nitrogen atom to which they are bonded from a heterocycloalkyl or heteroaryl radical.


Of highest interest are compounds of Formula III wherein:

    R represents an arylalkanoyl, aryloxycarbonyl, aryloxyalkanoyl, alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, or disubstituted aminoalkanoyl, or mono-or dialkylaminocarbonyl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen or which they are attached represent a heterocycloalkyl or heteroaryl radical;
    R1, R1′ and R1′′ independently represent hydrogen, methyl, ethyl, benzyl, phenylpropyl, —C(O)NH2 and propargyl radicals;
    R2 represents CH3SCH2CH2—, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;
    R3 represents propyl, isobutyl, isoamyl, n-butyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl radicals; and
    R4 and R5 independently represent hydrogen and methyl, ethyl, i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenyl radicals, or together with the nitrogen atom to which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl radical.


Another family of compounds of particular interest within Formula I are compounds embraced by Formula IV:




wherein:

    R represents hydrogen, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(SC6H5), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;
    R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, —NO2, —C≡N, CF3, —OR9, —SR9, wherein R9 represents hydrogen and alkyl;
    R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide derivatives thereof;
    R4 and R5 independently represent hydrogen and radicals as defined for R3 or together with a nitrogen atom to which they are bonded form a heterocycloalkyl or a heteroaryl radical.


A more preferred family of compounds within Formula IV consists of compounds wherein

    R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents hydrogen, alkyl and alkenyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, tert-leucine, S-methyl cysteine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine;
    R2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula —OR9 and —SR9 wherein R9 represents hydrogen and alkyl and halogen radicals;
    R3 represents alkyl, halalkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl radicals; and
    R4 and R5 independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocycloalkyl and heterocycloalkylalkyl radicals, or R4 and R5 together with the nitrogen atom to which they are bonded from a heterocycloalkyl or heteroaryl radical.


Of highest interest are compounds within Formula IV wherein

    R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
    R′ represents hydrogen and radicals as defined for R3 or R and R′ together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
    R1 represents hydrogen, methyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine, and allo-threonine side chains;
    R2 represents CH3SCH2CH2—, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;
    R3 represents propyl, isobutyl, isoamyl, n-butyl, cyclohexyl, cyclohexylmethyl, benzyl and pyridylmethyl radicals; and
    R4 and R5 independently represent hydrogen and methyl, ethyl, i-propyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenyl radicals, or R4 and R5 together with the nitrogen atom to which they are bonded form a pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl radical.


As utilized herein, the term “alkyl”, alone or in combination, means a straight-chain or branched-chain alkyl radical containing from 1 to about 10, preferably from 1 to 8, carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like. The term “alkenyl”, alone or in combination, means a straight-chain or branched-chain hydrocarbon radial having one or more double bonds and containing from 2 to about 18 carbon atoms preferably from 2 to 8 carbon atoms. Examples of suitable alkenyl radicals include ethenyl, propenyl, 1,4-butadienyl, 12-octadecene and the like. The term “alkynyl”, alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing from 2 to about 10 carbon atoms, preferably from 2 to 8 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl, (propargyl), butynyl and the like. The term “alkoxy”, alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. The term “cycloalkyl”, alone or in combination, means a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl radical wherein each cyclic moiety contains from about 3 to about 8 carbon atoms and is cyclic. The term “cycloalkylalkyl” means an alkyl radical as defined above which is substituted by a cycloalkyl radical containing from about 3 to about 8, preferably from 3 to 6 carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. The term “aryl”, alone or in combination, means a phenyl or naphthyl radical which optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, haloalkyl and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like. The term “aralkyl”, alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like. The term “aralkoxy carbonyl”, alone or in combination, means a radical of the formula —C(O)—O-aralkyl in which the term “aralkyl” has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl. The term “aryloxy” means a radical of the formula aryl-O— in which the term aryl has the significance given above. The term “alkanoyl”, alone or in combination, means arm acyl radical derived from an alkanecarboxylic acid wherein alkane means a radical as defined above for alkyl. Examples of alkanoyl radicals include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term “cycloalkylcarbonyl” means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid which is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl,2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The term “aralkanoyl” means an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl,4-methoxyhydrocinnamoyl, and the like. The term “aroyl” means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2 naphthoyl, 6-(benzyloxycarbonyl-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like. The heterocyclyl or heterocycloalkyl portion of a heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkoxycarbonyl, or heterocyclyalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., —NH—) by alkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. N═—) by oxido and which is attached via a carbon atom. The heteroaryl portion of a heteroaroyl, heteroaryloxycarbonyl, or a heteroaralkoxy carbonyl group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle which contains the hetero atoms and is optionally substituted as defined above with respect to the definition of heterocyclyl. Such heterocyclyl and heteroaryl radicals have from four to about 12 ring members, preferably from 4 to 10 ring members. Examples of such heterocyclyl and heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol 4-yl, 1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, thienyl, triazolyl, oxazolyl, thiazolyl, indolyl (e.g., 2-indolyl, etc.), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, etc.), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, etc.), tetrahydroauinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, etc.), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, etc.), quinoxalinyl, β-carbolinyl, 2-benzofurancarbonyl, 1-,2-,4- or 5-benzimidazolyl, and the like. The term “cycloalkylalkoxycarbonyl” means an acyl group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O—COOH wherein cycloalkylalkyl has the significance given above. The term “aryloxyalkanoyl” means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term “heterocyclyloxycarbonyl” means an acyl group derived from heterocyclyl-O—COOH wherein heterocyclyl is as defined above. The term “heterocyclylalkanoyl” is an acyl radical derived from a heterocyclyl-substituted alkane carboxylic acid wherein heterocyclyl has the significance given above. The term “heterocyclylalkoxycarbonyl” means an acyl radical derived from a heterocyclyl-substituted alkane-O—COCH wherein heterocyclyl has the significance given above. The term “heteroaryloxycarbonyl” means an acyl radical derived from a carboxylic acid represented by heteroaryl-O—COOH wherein heteroaryl has the significance given above. The term “aminocarbonyl” alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amino-substituted carboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term “aminoalkanoyl” means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term “halogen” means fluorine, chlorine, bromine or iodine. The term “haloalkyl” means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like. The term “leaving group” generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
Procedures for preparing the compounds of Formula I are set forth below. It should be noted that the general procedure is shown as is relates to preparation of compounds having tae specified stereochemistry, Nor example, wherein the absolute stereochemistry about the hydroxyl group is designated as (R), which is the preferred stereochemistry for the compounds of the present invention. However, such procedures are generally applicable to those compounds of opposite configuration, e.g., where the stereochemistry about the hydroxyl group is (S). In addition, the compounds having the (R) stereochemistry can be utilized to produce those having the (S) stereochemistry. For example, a compound having the (R) stereochemistry can be inverted to the (S) stereochemistry using well-known methods.
Preparation of Compounds of Formula I
The compounds of the present invention represented by Formula I above can be prepared utilizing the following general procedure. This procedure is schematically shown in the following Schemes I and II:








An N-protected chloroketone derivative of an amino acid having the formula:




wherein P represents an amino protecting group, and R2 is as defined above, is reduced to the corresponding alcohol utilizing an appropriate reducing agent. Suitable amino protecting groups are well known in the art and include carbobenzoxy, t-butoxycarbonyl, and the like. A preferred amino protecting group is carbobenzoxy. A preferred N-protected chloroketone is N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone. A preferred reducing agent is sodium borohydride. The reduction reaction is conducted at a temperature of from −10° C. to about 25° C., preferably at about 0° C., in a suitable solvent system such as, for example, tetrahydrofuran, and the like. The N-protected chloroketones are commercially available, e.g., such as from Bachem, Inc., Torrance, Calif. Alternatively, the chloroketones can be prepared by the procedure set forth in S. J. Fittkau, J. Prakt. Chem., 315, 1037 (1973), and subsequently N-protected utilizing procedures which are well known in the art.

The halo alcohol can be utilized directly, as described below, or, preferably, is then reacted, preferably at room temperature, with a suitable base in a suitable solvent system to produce an N-protected amino epoxide of the formula:




wherein P and R2 are as defined above. Suitable solvent systems for preparing the amino epoxide include ethanol, methanol, isopropanol, tetrahydrofuran, dioxane, and the like including mixtures thereof. Suitable bases for producing the epoxide from the reduced chloroketone include potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBU and the like. A preferred base is potassium hydroxide.

Alternatively, a protected amino epoxide can be prepared starting with an L-amino acid which is reacted with a suitable amino-protecting group in a suitable solvent to produce an amino-protected L-amino acid ester of the formula:




wherein P1 and P2 independently represent hydrogen, benzyl and amino-protecting groups (as defined above), provided that P1 and P2 are not both hydrogen; P3 represents carboxyl-protecting group, e.g., methyl, ethyl, benzyl, tertiary-butyl and the like; and R2 is as defined above.

The amino-protected L-amino acid ester is then reduced, to the corresponding alcohol. For example, the amino-protected L-amino acid ester can be reduced with diisobutylaluminum hydride at −78° C. in a suitable solvent such as toluene. The resulting alcohol is then converted, for example, by way of a Swern oxidation, to the corresponding aldehyde of the formula:




wherein P1, P2 and R2 are as defined above. Thus, a dichloromethane solution of the alcohol is added to a cooled (−75 to −68° C.) solution of oxalyl chloride in dichloromethane and DMSO in dichloromethane and stirred for 35 minutes.

The aldehyde resulting from the Swern oxidation is then reacted with a halomethyllithium reagent, which reagent is generated in situ by reacting an alkyllithium or arylithium compound with a dihalomethane represented by the formula X1CH2X2 wherein X1 and X2 independently represent I, Br or Cl. For example, a solution of the aldehyde and chloroiodomethane in THF is cooled to −78° C. and a solution of n-butyllithium in hexane is added. The resulting product is a mixture of diastereomers of the corresponding amino-protected epoxides of the formulas:




The diastereomers can be separated e.g., by chromatography, or, alternatively, once reacted in subsequent steps the diastereomeric products can be separated. For compounds having the (S) stereochemistry, a D-amino acid can be utilized in place of the L-amino acid.

The amino epoxide is then reacted, in a suitable solvent system, with an equal amount, or preferably an excess of, a desired amine of the formula:

R3NH2 

wherein R3 is hydrogen or is as defined above. The reaction can be conducted over a wide range of temperatures, e.g., from about 10° C. to about 100° C., but is preferably, but not necessarily, conducted at a temperature at which the solvent begins to reflux. Suitable solvent systems include protic, non-protic and dipolar aprotic organic solvents such as, or example, those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, and toluene, N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A preferred solvent is isopropanol. Exemplary amines corresponding to the formula R3NH2 include benzyl amine, isobutylamine, n-butyl amine, isopentyl amine, isoamylamine, cyclohexanemethyl amine, naphthylene methyl amine and the like. The resulting product is a 3-(N-protected amino)-3-(R2)-1-(NHR3)-propan-2-ol derivative thereinafter referred to as an amino alcohol) can be represented by the formulas:





wherein P, P1, P2, R2 and R3 are as described above. Alternatively, a haloalcohol can be utilized in place of the amino epoxide.

The amino alcohol defined above is then reacted in a suitable solvent with a sulfamoyl halide, e.g. sulfamoyl chloride (R4R5NSO2Cl or R4HNSO2Cl) or sulfamoyl anhydride in the presence of an acid scavenger. Suitable solvents in which the reaction can be conducted include methylene chloride, cetrahydrofuran. Suitable acid scavengers include triethylamine, pyridine. The resulting sulfamic acid derivative can be represented, depending on the epoxide utilized, by the formulas;




wherein P, P1, P2, R2, R3, R4 and R5 are as defined above. These intermediates are useful for preparing inhibitor compounds of the present invention and are also active inhibitors of retroviral proteases.

The sulfamoyl halides of the formula R4NHSO2X can be prepared by the reaction of a suitable isocyanate of the formula R4NCO with fuming sulfuric acid to produce the corresponding sulfamate which is then converted to the halide by well known procedures, such as by treating the sulfamate with PCl5. Alternatively the isocyanate can be treated with chlorosulfonic acid to produce the corresponding sulfamoyl chloride directly.
The sulfamoyl halides of the formula R4R5NSO2Cl can be prepared by reacting an amine of the formula R4R5NH, preferably as a salt such as the hydrochloride, with sulfuryl chloride in a suitable solvent such as acetonitrile. The reaction mixture is gradually warmed to reflux temperature and maintained at the reflux temperature until the reaction is complete. Alternatively, sulfamoyl halides of the formula R4R5NSO2Cl can be prepared by reacting an amine of the formula R4R5NH with sulfuryl chloride in boiling MeCN as disclosed in Matier et al., J. Med. Chem., 15, No. 5, p. 538 (1972).
Following preparation of the sulfamic acid derivative, the amino protecting group P or P1 and P2 amino protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of the protecting group, e.g., removal of a carbobenzoxy group, by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. Where the protecting group is a t-butoxycarbonyl group, it can be removed utilizing an inorganic or organic acid, e.g., HCl or trifluoroacetic acid, in a suitable solvent system, e.g., dioxane or methylene chloride. The resulting product is the amine salt derivative. Following neutralization of the salt, the amine is then reacted with an amino acid or corresponding derivative thereof represented by the formula (PN[CR1′ R1′′]tCH(R1)COOH) wherein t, R1, R1′ and R1′′ are as defined above, to produce the antiviral compounds of the present invention having the formula:




wherein t, P, R1, R1′, R1′′, R2, R3, R4 and R5 are as defined above. Preferred protecting groups in this instance are a benzyloxycarbonyl group or a t-butoxycarbonyl group. Where the amine is reacted with a derivative of an amino acid, e.g., when t=1 and R1′ and R1′′ are both H, so that the amino acid is a β-amino acid, such β-amino acids can be prepared according to the procedure set forth in a copending application, U.S. Ser. No. 07/345,808. Where t is 1, one of R1′ and R1′′ is H and R1 is hydrogen so that the amino acid is a homo-β-amino acid, such homo-β-amino acids can be prepared by the procedure set forth in a copending application, U.S. Ser. No. 07/853,561. Where t is C and R1 is alkyl, alkenyl, alkynyl, cycloalkyl, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2[S(O)CH3], —C(CH3)2[S(O2)CH3], or an amino acid side chain, such materials are well known and many are commercially available from Sigma-Aldrich.

The N-protecting group can be subsequently removed, if desired, utilizing the procedures described above, and then reacted with a carboxylate represented by the formula:




wherein R is as defined above and L is an appropriate leaving group such as a halide. Preferably, where R1 is a side chain of a naturally occurring α-amino acid, R is a 2-quinoline carbonyl group derived from N-hydroxysuccinimide-2-quinoline carboxylate, i.e., L is hydroxy succinimide. A solution of the free amine (or amine acetate salt) and about 1.0 equivalent of the carboxylate are mixed in an appropriate solvent system and optionally treated with up to five equivalents of a base such as, for example, N-methylmorpholine, at about room temperature. Appropriate solvent systems include tetrahydrofuran, methylene chloride or N,N-dimethylformamide, and the like, including mixtures thereof.

Alternatively, the protected amino alcohol from the epoxide opening can be further protected at the newly introduced amino group with a protecting group P′ which is not removed when the first protecting P is removed. One skilled in the art can choose appropriate combinations of P and P′. One suitable choice is when P is Cbz and P′ is Boc. The resulting compound represented by the formula:




can be carried through the remainder of the synthesis to provide a compound of the formula:





and the new protecting group P′ is selectively removed, and following deprotection, the resulting amine reacted to form the sulfamic acid derivative as described above. This selective deprotection and conversion to the sulfamic acid can be accomplished at either the end of the synthesis or at any appropriate intermediate step if desired.

It is contemplated that for preparing compounds of the Formulas having R6, the compounds can be prepared following the procedure set forth above and, prior to coupling the sulfonamide derivative or analog thereof, e.g. coupling to the amino acid PNH(CH2)tCH(R1)COOH, carried through a procedure referred to in the art as reductive amination. Thus, a sodium cyanoborohydride and an appropriate aldehyde or ketone can be reacted with the sulfonamide derivative compound or appropriate analog at room temperature in order to reductively aminate any of the compounds of Formulas I–IV. It is also contemplated that where R3 of the amino alcohol intermediate is hydrogen, the inhibitor compounds of the present invention wherein R3 is alkyl, or other substituents wherein the α-C contains at least one hydrogen, can be prepared through reductive amination of the final product of the reaction between the amino alcohol and the amine or at any other stage of the synthesis for preparing the inhibitor compounds.
Contemplated equivalents of the general formulas set forth above for the antiviral compounds and derivatives as well as the intermediates are compounds otherwise corresponding thereto and having the same general properties, such as tautomers thereof as well as compounds, wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than that indicated. In addition, where a substituent is designated as, or can be, a hydrogen, the exact chemical nature of a substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical or a halogen, hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.
The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The following Examples 1 through 9 illustrate preparation of intermediates. These intermediates are useful in preparing the inhibitor compounds of the present invention as illustrated in Examples 13–17. In addition, the intermediates of Examples 4–9 are also retroviral protease inhibitors and inhibit, in particular, HIV protease.
EXAMPLE 1




Preparation of N[3 (S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isoamylamine
Part A:
To a solution of 75.0 g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of 807 mL of methanol and 807 mL of tetrahydrofuran at −2° C., was added 13.17 g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one hundred minutes. The solvents were removed under reduced pressure at 40° C. and the residue dissolved in ethyl acetate (approx. 1 L). The solution was washed sequentially with 1M potassium hydrogen sulfate, saturated sodium bicarbonate and then saturated sodium chloride solutions. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced pressure. To the resulting oil was added hexane (approx. 1 L) and the mixture warmed to 60° C. with swirling. After cooling to room temperature, the solids were collected and washed with 2 L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3 g (43% yield) of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp 150–151° C. and M+Li+=340.
Part B:
To a solution of 6.52 g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at room temperature, was added 32.3 g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes, the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate, filtering and stripping, one obtains 27.9 g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3 g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102–103° C. and MH+ 298.
Part C:
A solution of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00 g, 3.36 mmol) and isoamylamine (4.90 g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was heated to reflux for 1.5 hours. The solution was cooled to room temperature, concentrated in vacuo and then poured into 100 mL of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 1.18 g, 95% of N=[[3(S)-phenylmethylcarbamoyl)amino-2(R)-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)]amine mp 108.0-109.5° C., MH+ m/z=371.
EXAMPLE 2




Preparation of N,N-dibenzyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane
Step A:
A solution of L-phenylalanine (50.0 g, 0.302 mol, sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 ml) is heated to 97° C. Benzyl bromide (108.5 ml, 0.912 mol) is then slowly added (addition time ̃25 min). The mixture is then stirred at 97° C. for 30 minutes. The solution is cooled to room temperature and extracted with toluene (2×250 ml). The combined organic layers are then washed with water, brine, dried over magnesium sulfate, filtered and concentrated to give an oil product. The crude product is then used in the next step without purification.
Step B:
The crude benzylated product of the above step is dissolved in toluene (750 ml) and cooled to −55° C. A 1.5 M solution of DIBAL-H in toluene (443.9 ml, 0.666 mol) is then added at a rate to maintain the temperature between −55° to −50° C. (addition time—1 hour). The mixture is stirred for 20 minutes at −55° C. The reaction is quenched at −55° C. by the slow addition of methanol (37 ml). The cold solution is then poured into cold (5° C.) 1.5 N HCl solution (1.8 L). The precipitated solid (approx. 138 g) is filtered off and washed with toluene. The solid material is suspended in a mixture of toluene (400 ml) and water (100 ml). The mixture is cooled to 5° C., treated with 2.5 N NaOH (186 ml) and then stirred at room temperature until the solid is dissolved. The toluene layer is separated from the aqueous phase and washed with water and brine, dried over magnesium sulfate, filtered and concentrated to a volume of 75 ml (89 g). Ethyl acetate (25 ml) and hexane (25 ml) are then added to the residue upon which the alcohol product begins co crystallize after 30 min., an additional 50 ml hexane is added to promote further crystallization. The solid is filtered off and washed with 50 ml hexane to give approximately 35 g of material. A second crop of matrial can be isolated by refiltering the mother liquor. The solids are combined and recrystallized from ethyl acetate (20 ml) and hexane (30 ml) to give, in 2 crops, approximately 40 g (40% from L-phenylalanine) of analytically pure alcohol product. The mother liquors are combined and concentrated (34 g). The residue is treated with ethyl acetate and hexane which provides an additional 7 g ( ̃7% yield) of slightly impure solid product. Further optimization in the recovery from the mother liquor is probable.
Step C:
A solution of oxalyl chloride (8.4 ml, 0.096 mol) in dichloromethane (240 ml) is cooled to −74° C. A solution of DMSO (12.0 ml, 0.155 mol) in dichloromethane 50 ml) is then slowly added at a rate to maintain the temperature at −74° C. (addition time  ̃1.25 hr). The mixture is stirred for 5 min. followed by addition of a solution of the alcohol (0.074 mol) in 100 ml of dichloromethane (addition time—20 min., temp. −75° C. to −68° C.). The solution is stirred at −78° C. for 35 minutes. Triethylamine (41.2 ml, 0.295 mol) is then added over 10 min. (temp. −78° to −68° C.) upon which the ammonium salt precipitated. The cold mixture is stirred for 30 min. and then water (225 ml) is added. The dichloromethane layer is separated from the aqueous phase and washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The residue is diluted with ethyl acetate and hexane and then filtered to further remove the ammonium salt. The filtrate is concentrated to give the desired aldehyde product. The aldehyde was carried on to the next step without purification.
Temperatures higher than −70° C. have been reported in the literature for the Swern oxidation. Other Swern modifications and alternatives to the Swern oxidations are also possible.
A solution of the crude aldehyde 0.074 mol and chloroiodomethane (7.0 ml, 0.096 mol) in tetrahydrofuran (285 ml) is cooled to −78° C. A 1.6 M solution of n-butyllithium in hexane (25 ml, 0.040 mol) is then added at a rate to maintain the temperature at −75° C. (addition time—15 min.). After the first addition, additional chloroiodomethane (1.6 ml, 0.022 mol) is added again, followed by n-butyllithium (23 ml, 0.037 mol), keeping the temperature at −75° C. The mixture is stirred for 15 min. Each of the reagents, chloroiodomethane (0.70 ml, 0.010 mol) and n-butyllithium (5 ml, 0.008 mol) are added 4 more times over 45 min. at −75° C. The cooling bath is then removed and the solution warmed to 22° C. over 1.5 hr. The mixture is poured into 300 ml of saturated aq. ammonium chloride solution. The tetrahydrofuran layer is separated. The aqueous phase is extracted with ethyl acetate (1×300 ml). The combined organic layers are washed with brine, dried over magnesium sulfate, filtered and concentrated to give a brown oil (27.4 g). The product could be used in the next step without purification. The desired diastereomer can be purified by recrystallization at a subsequent step.
Alternately, the product could be purified by chromatography.
EXAMPLE 3




Preparation of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine
A solution of N-benzyloxycarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenyl butane (50.0 g, 0.168 mol) and isobutylamine (246 g, 3.24 mol, 20 equivalents) in 650 mL of isopropyl alcohol was heated to reflux for 1.25 hours. The solution was cooled to room temperature, concentrated in vacuo and then poured into 1 L of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 57.56 g, 92% of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl]N-isobutylamine, mp 108.0–109.5° C., MH+m/z=371.
EXAMPLE 4




Preparation of phenylmethyl[2R-hydroxy-3-[[(dimethylamino)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate
The product from Example 3 (740 mg, 2.0 mmol) and diisopropylethylamine (382 uL, 2.2 mmol) were dissolved in dichloromethane (1.5 mL) at room temperature. To this was added dimethylsulfamoyl chloride (354 uL, 3.3 mmol). The reaction was stirred for 24 hours. The reaction mixture was chromatographed on silica gel (50 gm) using 1% ethanol in chloroform. The product fractions were pooled and concentrated to an oil. Anal. Calcd for C24H35N3O5S: C, 60.35; H, 7.39; N, 8.80. Found: C, 60.18; H, 7.40; N, 8.55.
EXAMPLE 5




Preparation of phenylmethyl[2R-hydroxy-3-[[(dimethylamino)sulfonyl](3-methylbutyl)amino]-1S-(phenylmethyl)propyl]carbamate
Part A
The procedure described in Example 1 was used to prepare N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl)-N-[(3-methylbutyl)]amine.
Part B
The product from Part A (192 mg, 0.5 mmol) and diisopropylethylamine (96 uL, 0.55 mmol) were dissolved in dichloromethane (10 mL) at room temperature. To this was added dimethylsulfamoyl chloride (59 uL, 0.55 mmol). The reaction was stirred for 120 hours, then concentrated on a rotary evaporator. The residue was chromatographed on silica gel (50 gm) using 2% methanol in dichloromethane. The product fractions were pooled and concentrated to an oil which solidified on standing. Anal. Calcd for C25H37N3O5S. 0.9H2O: C, 59.13; H, 7.64; N, 8.27; S, 6.31. Found: C, 58.81; H, 7.38; N, 8.62; S, 6.70.
EXAMPLE 6




Preparation of phenylmethyl[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]carbamate
Part A:
To a stirred solution of 3.88 gm (2 mL) of 30% fuming sulfuric acid in nitromethane (10 mL) was added dropwise n-butylisocyanate (3.83 mL, 34 mmoles) at 0 C. After the addition was completed, the suspension was heated in an oil bath at 120 C. for 30 min. The reaction was cooled and filtered. The collected sulfamic acid crystals were air dried, wt. 4.73 gm (91%).
Part B:
A suspension of n-butyl sulfamic acid (1.92 gm, 12.53 mmoles) and phosphorus pentachloride (2.61 gm, 12.53 mmoles) in benzene (20 mL) was warmed gently to initiate gas evolution. The reaction mixture was stirred at room temperature for 0.5 h., during which time a cloudy solution resulted. The cloudy solution was heated to reflux for 0.5 h., then was concentrated. The product n-butyl sulfamoyl chloride was isolated by vacuum distillation (120 C., 300 millitorr), 730 mg (liq.) (34%).
Part C:
The amine alcohol from Example 3 (370 mg, 1 mmole) was dissolved in 3 mL of dichloromethane and treated with diisopropylethylamine (278 uL, 2 mmoles), followed by chlorotrimethylsilane (126 uL; 1 mmole). The reaction mixture was stirred at r.t. for 1 h. n-Butyl sulfamoyl chloride from Part B (171 mg, 1 mmole) was added and the mixture was stirred at r.t. overnight. After removal of dichloromethane the oily residue was taken up in ethyl acetate and washed successively with 5% citric acid, saturated sodium bicarbonate, brine, dried over sodium sulfate and the solvent was evaporated to give 512 mg of product (oil).
The oily product (510 mg) was dissolved in dichloromethane (3 mL) and was treated with 2 mL of 4N HCl in dioxane. After 15 min. methanol (5 mL) was added and the solution was stirred for an additional 15 min. Solvent and excess reagent were evaporated. The product was isolated by silica gel chromatography co give 257 mg of phenylmethyl [3-[[(butylamino)sulfonyl] (2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl] carbamate. Anal. Calcd for C26H39N3O5S: C, 61.76; H, 7.77; N, 8.31. Found: C, 61.89; H, 7.66; N, 8.18.
EXAMPLE 7




Preparation of phenylmethyl[2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate
Part A:
1-methylpiperazine hydrochloride (3.46 gm, 20 mmoles) was added in portions within 15 min. to a stirred solution of sulfuryl chloride (8.99 gm, 67 mmoles) in acetonitrile (40 mL). The suspension was gradually warmed to reflux and maintained at reflux temperature overnight. A brown solution was obtained. After cooling to r.t., the crystals were collected by filtration, wt. 2.3 gm. A sample of 4-methyl-1-piperazine sulfamoyl chloride. HCl was recrystallized from methanol. Anal. Calcd. for C5H12N2O2Cl2S: C, 25.54; H, 5.14; N, 11.91; Cl, 30.16. Found: C, 25.54; H, 4.91; N, 11.91; Cl, 29.88.
Part B:
N(3 (S)-benzyloxycarbonylamino-2 (R)-hydroxy-4-phenylbutyl]-N-isobutylamine (370 mg, 1.0 mmole), prepared according to the procedure in Example 3 was mixed with DIEA (280 uL, 2.0 mmoles) and 4-methyl-1-piperazine sulfamoyl chloride.HCl (240 mg, 1.0 mmole) in 6 mL of dichloromethane. The reaction mixture was stirred for 5 days. After filtration, the filtrate was concentrated to an oil, which was taken up in ethyl acetate. The ethyl acetate solution was washed with sodium bicarbonate solution, brine and dried over sodium sulfate. After evaporation, phenylmethyl [2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate was obtained (412 mg).
EXAMPLE 8




Preparation of phenylmethyl[2-hydroxy-3-[[(1,1-dimethyl)amino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate
Part A:
A 25 mL two-necked RB flask, equipped with a reflux condenser and dropping funnel and under a nitrogen atmosphere, was charged with t-butanol (207 uL, 2.2 mmoles) and 5 mL of hexane. Chlorosulfonyl isocyanate (192 uL, 2.2 mmoles) in 3 mL of hexane was added dropwise. Upon warming a homogeneous solution was obtained. The solution was heated at gentle reflux for 45 min., then was cooled to r.t. Solvent was removed under a steady stream of nitrogen. The crude t-butyl sulfamoyl chloride (a liquid) was used without further purification.
Part B:
N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isobutylamine (370 mg, 1.0 mmole), prepared according to the procedure in Example 3 was mixed with DIEA (139 uL, 1 mmole) in 5 mL of dichloromethane. Chlorotrimethylsilane (126 uL, 1 mmole) was added. After 1 h., additional DIEA (160 uL) was added, followed by a dichloromethane solution (5 mL) containing 1.1 mmole of t-butyl sulfamoyl chloride from Part A. The reaction mixture was stirred for 2 days. Solvent was removed under aspirator pressure. The oily residue was taken up in ethyl acetate and washed with 5% citric acid, saturated sodium bicarbonate, brine, dried over sodium sulfate and evaporated to an oily residue (380 mg).
The crude product was stirred in 4N HCl in dioxane (6 mL) for 15 min. after the addition of 4 mL of methanol to the reaction mixture, the solution was stirred for an additional 15 min, then concentrated to an oily residue. The product, phenylmethyl [2R-hydroxy-3-[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl] carbamate was obtained after silica gel chromatography (188 mg, 37%). MS (MH)+=506.
EXAMPLE 9
Preparation of phenylmethyl[2R-hydroxy-3-[[(piperidyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate
Part A:
The product of Example 3 (750 mg, 2.02 mmol) and triethylamine (280 uL, 2.02 mmol) were dissolved dichloromethane (8.0 mL) at room temperature. To this was added piperidinesulfamoyl chloride (371 mg, 2.02 mmol). The reaction was stirred for 72 hours and then concentrated. The residue was chromatographed on silica gel (50 gm) using 5% methanol in dichloromethane. The product fractions were pooled and concentrated to an oil, 945 mg. TLC (silica/5% MeOH in CH2C12) showed two spots. Rechromatographed. Anal. Calcd for C27H39N3O5S: C. 62.63; H, 7.51; N, 8.06. Found: C, 62.64; H, 7.59; N, 8.12.
Part B:
The product of Part A (430 mg) was combined with 10% Pd/C in methanol (10 mL) and hydrogenated at 5 psi for 1.4 hours at room temperature. The catalyst was removed by filtration and the solvent evaporated to afford the product as an oil, 305 mg.
Part C:
To a solution of Cbz-L-t—leucine (236 mg, 0.89 mmol) in DMF (2 mL) was added HOBt 115 mg, 0.85 mmol) and EDC (163 mg, 0.85 mmol). The reaction was stirred at room temperature for 1 hour and then a solution of the product from part B (305 mg, 0.79 mmol) in DMF (2 mL) was added. The reaction was stirred for 18 hours then concentrated. The residue was taken up in ethyl acetate and washed with 0.5% HCl solution, saturated aqueous NaHCO3, and saturated aqueous NaCl (50 mL each). The organic solution was dried (Na2SO4), filtered and concentrated to a foam, 410 mg. 1H NMR supports product.
Part D:
The product of Part C (410 mg) was combined with 10% Pd/C in methanol (10 mL) and hydrogenated at 5 psi for 2.0 hours at room temperature. The catalyst was removed by filtration and the solvent evaporated to afford the product as an foam, 320 mg.
Part E:
To a solution of the product of Part D (310 mg, 0.62 mmol) in dichloromethane (10 mL) was added diisopropylethylamine (130 uL, 0.75 mmol) and chloroacetic anhydride (117 mg, 0.68 mmol) at 0 C. The reaction was allowed to warm to room temperature and stir one hour. The solvent was removed and the residue taken up in ethyl acetate (50 mL). The organic solution was washed with 5% citric acid, saturated NaHCO3, and saturated NaCl (50 mL each). The solution was dried (Na2SO4), filtered and concentrated to give a solid, 350 mg.
Part F:
The product of Part E (350 mg, 0.61 mmol) was combined with 40% aqueous dimethylamine (380 uL, 3.05 mmol) in isopropanol (10 mL). The reaction was stirred for 18 hours then concentrated. The residue was taken up in ethyl acetate (50 mL) and washed with water, saturated NaHCO3, and saturated NaCl (50 mL each). The solution was dried (Na2SO4), filtered and concentrated to a solid. The solid was chromatographed on silica gel using 2% MeOH in dichloromethane. The product fractions were pooled and concentrated to give a white solid. Anal. Calcd for C29H51N5O5S. 0.25H2O: C, 59.41; H, 8.77; N, 1.94. Found: C, 59.35; H, 8.78; N, 11.63.
EXAMPLE 10
Following the procedures of the previous Examples 1–9, the intermediate compounds set forth in Tables 1A, 1B and 1C were prepared.







TABLE 1A













 











R3
R4
R5







isobutyl
CH3
CH3



isoamyl
CH3
CH3



isobutyl
CH2CH2CH2CH3
H



isobutyl
C(CH3)3
H

















TABLE 1B













 









Entry
R4
R5





1
CH3
CH3


2
H
CH3


3
H
(CH2)3CH3


4
H
CH(CH3)2


5
H
C(CH3)3


6
H
cyclohexyl


7
R4 & R5 = pyrrolidinyl
















TABLE 1C













 










Entry
R3
R4
R5





A
isobutyl
methyl
H


B
p-fluorobenzyl
methyl
methyl


C
isobutyl
isopropyl
H









 


D
isobutyl






 










E
isobutyl
phenyl
H


 









F
isobutyl






 


G
isobutyl






 










H
benzyl
t-butyl
H


I
cyclohexylmethyl
t-butyl
H


J
isobutyl
C(CH3)2CO2Me
H


K
cyclohexyl
t-butyl-
H


L
isobutyl
(CH2)2OCH2C6H5
H


M
isobutyl
cyclohexyl
H









The following Examples 11–13 illustrate preparation of β-amino acid intermediates. These intermediates can be coupled to the intermediate compounds of Examples 1–10 to produce inhibitor compounds of the present invention containing β-amino acids.
EXAMPLE 11
A. Preparation of 4(4-methoxybenzyl)itaconate




A 5 L three-necked round bottomed flask equipped with constant pressure addition funnel, reflux condenser, nitrogen inlet, and mechanical stirrer was charged with itaconic anhydride (660.8 g, 5.88 mol) and toluene (2300 mL). The solution was warmed to reflux and treated with 4-methoxybenzyl alcohol (812.4 g, 5.88 mol) dropwise over a 2.6 h period. The solution was maintained at reflux for an additional 1.5 h and then the contents were poured into three 2 L erlenmeyer flasks to crystallize. The solution was allowed to cool to room temperature whereupon the desired mono-ester crystallized. The product was isolated by filtration on a Buchner funnel and air dried to give 850.2 g, 58% of material with mp 83–85° C., a second crop, 17% was isolated after cooling of the filtrate in an ice bath. 1H NMR (CDCl3) 300 MHz 7.32 (d, J=8.7 Hz, 2H), 6.91 (d, J=8.7 Hz, 2H), 6.49 (s, 1H), 5.85 (s, 1H), 5.12 (s, 2H), 3.83 (s, 3H), 3.40 (s, 2H).
B. Preparation of Methyl 4(4-methoxybenzyl) itaconate




A 5 L three-necked round bottomed flask equipped with reflux condenser, nitrogen inlet, constant pressure addition funnel and mechanical stirrer was charged with 4(4-methoxybenzyl) itaconate (453.4 g, 1.81 mol) and treated with 1.5-diazabicyclo[4.3.0]non-5-ene (275.6 g, 1.81 mol), (DBN), dropwise so that the temperature did not rise above 15° C. To this stirring mixture was added a solution of methyl iodide (256.9 g, 1.81 mol) in 250 mL of toluene from the dropping funnel over a 45 m period. The solution was allowed to warm to room temperature and stirred for an additional 3.25 h.
The precipitated DBN hydroiodide was removed by filtration, washed with toluene and the filtrate poured into a separatory funnel. The solution was washed with sat. aq. NaHCO3 (2×500 mL), 0.2N HCl (1×500 mL), and brine (2×500 mL), dried over anhyd. MgSO4, filtered, and the solvent removed in vacuo. This gave a clear colorless oil, 450.2 g, 94% whose NMR was consistent with the assigned structure. 1H NMR (CDCl3) 300 MHz 7.30 (d, J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 2H), 6.34(s, 1H), 5.71(s, 1H), 5.09(s, 2H), 3.82(s, 3H), 3.73(s, 3H), 3.38(s, 2H). 13C NMR (CDCl3) 170.46, 166.47, 159.51, 133.55, 129.97, 128.45, 127.72, 113.77, 66.36, 55.12, 51.94, 37.64.
C. Preparation of Methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate




A 500 mL Fisher-Porter bottle was charged with methyl 4(4-methoxybenzyl) itaconate (71.1 g, 0.269 mol), rhodium (R,R) DiPAMP catalyst (204 mg, 0.269 mmol, 0.1 mol %) and degassed methanol (215 mL). The bottle was flushed 5 times with nitrogen and 5 times with hydrogen to a final pressure of 40 psig. The hydrogenation commenced immediately and after ca. 1 h the uptake began to taper off, after 3 h the hydrogen uptake ceased and the bottle was flushed with nitrogen, opened and the contents concentrated on a rotary evaporator to give a brown oil that was taken up in boiling iso-octane (ca. 200 mL, this was repeated twice), filtered through a pad of celite and the filtrate concentrated in vacuo to give 66.6 g, 93% of a clear colorless oil, 1H NMR (CDCl3 300 MHz 7.30(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 5.08(s, 2H), 3.82(s, 3H), 3.67(s, 3H), 2.95(ddq, J=5.7, 7.5, 8.7 Hz, 1H), 2.79(dd, J=8.1, 16.5 Hz, 1H), 2.45(dd, J=5.7, 16.5 Hz, 1H), 1.23(d, J=7.5 Hz, 3H).
D. Preparation of Methyl 2(R)-methylsuccinate
A 3 L three-necked round-bottomed flask equipped with a nitrogen inlet, mechanical stirrer, reflux condenser and constant pressure addition funnel was charged with methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate (432.6 g, 1.65 mol) and toluene (1200 mL). The stirrer was started and the solution treated with trifluoroacetic acid (600 mL) from the dropping funnel over 0.25 h. The solution turned a deep purple color and the internal temperature rose Us 45° C. After stirring for 2.25 h the temperature was 27° C. and the solution had acquired a pink color. The solution was concentrated on a rotary evaporator. The residue was diluted with water (2200 mL) and sat. aq. NaHCO3 (1000 mL). Additional NaHCO3 was added until the acid had been neutralized. The aqueous phase was extracted with ethyl acetate (2×1000 mL) to remove the by-products and the aqueous layer was acidified to pH=1.8 with conc. HCl. This solution was extracted with ethyl acetate (4×1000 mL), washed with brine, dried over anhyd. MgSO4, filtered and concentrated on a rotary evaporator to give a colorless liquid 251 g, >100% that was vacuum distilled through a short path apparatus cut 1: bath temperature 120° C. @>1 mm, bp 25–29° C.; cut 2: bath temperature 140° C. @ 0.5 mm, bp 95–108° C., 151 g, [α]d @ 25° C.=+1.38° C. (c=15.475, MeOH), [α]d=+8.48° C. (neat); cut 3: bath temperature 140° C., bp 108° C., 36 g, [α]d @ 25° C.=+1.49° C.(c=15.00, MeOH), [α]d=+8.98° C. (neat). Cuts 2 and 3 were combined to give 189 g, 78% of product, 1H NMR (CDCl3) 300 MHz 11.6 (brs, 1H), 3.72 (s, 3H), 2.92(ddq, J=5.7, 6.9, 8.0 Hz, 1H), 2.81(dd, J=8.0, 16.8 Hz, 1H), 2.47(dd, J=5.7, 16.8 Hz, 1H), 1.26(d, J=6.9 Hz, 3H).
E. Preparation of Methyl Itaconate




A 50 mL round bottomed flask equipped with reflux condenser, nitrogen inlet and magnetic stir bar was charged with methyl 4(4-methoxybenzyl) itaconate (4.00 g, 16 mmol, 12 mL of touluene and 6 mL of trifluoroacetic acid. The solution was kept at room temperature for 18 hours and then the volatiles were removed in vacuo. The residue was taken up in ethyl acetate and extracted three times with saturated aqueous sodium bicarbonate solution. The combined aqueous extract was acidified to pH=1 with aqueous potassium bisulfate and then extracted three times with ethyl acetate. The combined ethyl acetate solution was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue was then vacuum distilled to give 1.23 g, 75% of pure product, bp 85–87 @ 0.1 mm. 1H NMR (CDCl3) 300 MHz 6.34(s, 1H), 5.73(s, 2H), 3.76(s, 3H), 3.38(s, 2H). 13C NMR (CDCl3) 177.03, 166.65, 129.220, 132.99, 52.27, 37.46.
F. Curtius Rearrangement of Methyl 2(R)-methylsuccinate
Preparation of Methyl N-Moz-α-methyl β-alanine




A 5 L four necked round bottomed flask equipped with a nitrogen inlet, reflux condenser, mechanical stirrer, constant pressure addition funnel, and thermometer adapter was charged with methyl 2(R)-methylsuccinate (184.1 g, 1.26 mol), triethylamine (165.6 g, 218 mL, 1.64 mol, 1.3 equivalents), and toluene (1063 mL). The solution was warmed to 85° C. and then treated dropwise with a solution of diphenylphosphoryl azide (346.8 g, 1.6 mol) over a period of 1.2 h. The solution was maintained at that temperature for an additional 1.0 h and then the mixture was treated with 4-methooxybenzyl alcohol (174.1 g, 1.26 mol) over a 0.33 h period from the dropping funnel. The solution was stirred at 88° C. for an additional 2.25 h and then cooled to room temperature. The contents of the flask were poured into a separatory funnel and washed with sat. aq. NaHCO3 (2×500 mL), 0.2N HCl (2×500 mL), brine (1×500 mL), dried over anhyd. MgSO4, filtered, and concentrated in vacuo to give 302.3 g, 85% of the desired product as a slightly brown oil. 1H NMR (CDCl3) 300 MHz 7.32(d, J=8.4 Hz, 2H), 6.91(d, J=8.4 Hz, 2H), 5.2(brm, 1H), 5.05(s, 2H), 3.83(s, 3H), 3.70(s, 3H), 3.35(m, 2H), 2.70(m, 2H), 1.20(d, J=7.2 Hz, 3H).
G. Hydrolysis of Methyl N-Moz-α-methyl β-alanine
Preparation of α-methyl β-alanine Hydrochloride




A 5 L three-necked round bottomed flask equipped with a reflux condenser, nitrogen inlet and mechanical stirrer was charged with methyl N-Moz-α-methyl β-alanine (218.6 g, 0.78 mol), glacial acetic acid (975 mL) and 12N hydrochloric acid (1960 mL). The solution was then heated to reflux for 3 h. After the solution had cooled to room temperature (ca. 1 h) the aqueous phase was decanted from organic residue (polymer) and the aqueous phase concentrated on a rotary evaporator. Upon addition of acetone to the concentrated residue a slightly yellow solid formed that was slurried with acetone and the white solid was isolated by filtration on a Buchner funnel. The last traces of acetone were removed by evacuation to give 97.7 g, 90% of pure product, mp 128.5–130.5° C. [α]d @ 25° C.=9.0° C. (c=2.535, Methanol). 1H NMR (D2O) 300 MHz 3.29(dd, J=8.6, 13.0 Hz, 1H), 3.16 (dd, J=5.0, 13.0 m Hz, 1H), 2.94(ddq, J=7.2, 5.0, 8.6 Hz, 1H), 1.30(d, J=7.2 Hz, 3H); 13C NMR (D2O) 180.84, 44.56, 40.27, 17.49.
H. Preparation of N-Boc α-Methyl β-Alanine




A solution of a-methyl b-alanine hydrochloride (97.7 g, 0.70 mol) in water (1050 mL) and dioxane (1050 mL) the pH was adjusted to 8.9 with 2.9N NaOH solution. This stirring solution was then treated with di-tert-butyl pyrocarbonate (183.3 g, 0.84 mol, 1.2 equivalents) all at once. The pH of the solution was maintained between 8.7 and 9.0 by the periodic addition of 2.5N NaOH is solution. After 2.5 h the pH had stabilized and the reaction was judged to be complete. The solution was concentrated on a rotary evaporator (the temperature was maintained at <40° C.). The excess di-tert-butyl pyrocarbonate was removed by extraction with dichloromethane and then the aqueous solution was acidified with cold 1N HCl and immediately extracted with ethyl acetate (4×1000 mL). The combined ethyl acetate extract was washed with brine, dried over anhyd. MgSO4, filtered and concentrated on a rotary evaporator to give a thick oil 127.3 g, 90% crude yield that was stirred with n-hexane whereupon crystals of pure product formed, 95.65 g, 67%, mp 76–78° C., [α]d @ 25° C.=−11.8° C. (c=2.4, EtOH). A second crop was obtained by concentration of the filtrate and dilution with hexane, 15.4 g, for a combined yield of 111.05 g, 78%. 1H NMR (acetone D6) 300 MHz 11.7 (brs, 1H), 6.05 (brs 1H), 3.35 (m, 1H), 3.22 (m, 1H), 2.50 (m, 1H), 1.45 (s, 9H), 1.19 (d, J=7.3 Hz, 3H); 13C NMR (acetone D6) 177.01, 79.28, 44.44, 40.92, 29.03, 15.50. Elemental analysis calc'd. for C9H17NO4: C, 53.19, H, 8.42; N, 6.89. Found: C, 53.36; H, 8.46; N, 6.99.
I. Preparation of N-4-Methoxybenzyloxycarbonyl α-Methyl β-Alanine
A solution of N-4-methoxybenzyloxycarbonyl α-methyl β-alanine methyl ester (2.81 g, 10.0 mmol) in 30 mL of 25% aqueous methanol was treated with lithium hydroxide (1.3 equivalents) at room temperature for a period of 2 h. The solution was concentrated in vacuo and the residue taken up in a mixture of water and ether and the phases separated and the organic phase discarded. The aqueous phase was acidified with aqueous potassium hydrogen sulfate to pH=1.5 and then extracted three times with ether. The combined ethereal phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to give 2.60 g, 97% of N-4-Methoxybenzyloxycarbonyl α-methyl β-alanine (N-Moz-AMBA) which was purified by recrystallization from a mixture of ethyl acetate and hexane to give 2.44 g, 91% of pure product, mp 96–97° C., MH+=268. 1H NMR (D6-acetone/300 MHz) 1.16 (3H, d, J=7.2 Hz), 2.70 (1H, m), 3.31 (2H, m), 3.31 (3H, s), 4.99 (2H, s), 6.92 (2H, 4, J=8.7 Hz), 7.13 (2H, d, J=8.7 Hz).
EXAMPLE 12
Following generally the procedure of Example 11, the β-amino acids set forth in Table 2 were prepared.







TABLE 2













 










Entry
R1
R1′
R1′′













1
—CH3
H
H


2
—CH(CH3)2
H
H


3
—C(CH3)3
H
H


4
H
H
H


5
H
—CH3
H


6
H
—CH3
—CH3


7
H
H
—CO2CH3


8
H
H
—CONH2


9
—CH2CH3
H
H


10
—CH2CH(CH3)2
H
H


11
—CH2C6H5
H
H


 


12




H
H


 


13




H
H


 


14
—CH2COOH
H
H


15
H
—CH(CH3)2
H


16
H
—CH2CH(CH3)2
H


 


17
H




H


 


18
H




H


 


19
H




H


 


20
H




H


 


21
H
-(CH2)3CH(C6H5)2
H









EXAMPLE 13
Utilizing generally the procedure set forth in Example 11, the following β-amino acid compounds were prepared.




EXAMPLE 14




Preparation of N-[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[[2-(dimethylamino)-1-oxoethyl]amino]dimethylbutanamide
Part A:
The product from Example 3 (357 mg, 0.71 mmol) in 10 mL of methanol was hydrogenated over 10% palladium on carbon (60 mg) for 5 hr. The mixture was then is filtered through Celite and concentrated to give the product as an oil (213 mg).
Part B:
The free amine from Part A (210 mg, 0.566 mmol) was coupled with N-CBZ-L-t-butylglycine (180 mg, 0.679 mmol) in the presence of N-hydroxybenzotriazole (92 mg, 0.679 mmol) and EDC (130 mg, 0.679 mmol) to yield 275 mg of phenylmethyl [[[1S-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-amino]carbonyl]-2,2-dimethylpropyl]carbamate after purification on silica column.
Part C:
The product from Part B (235 mg) in methanol was hydrogenated over 10% palladium on carbon (50 mg) for 4 h. The mixture was filtered through Celite and concentrated to give the product as an oil (173 mg, 0.369 mmol). This free amine was then dissolved in 3 mL of dichloromethane and acylated with bromo acetyl chloride (34 uL, 0.406 mmol) in the presence of DIEA (62 uL, 0.443 mmol) for 2 h. The crude mixture (190 mg, 0.32 mmol) was dissolved in 1 mL of isopropanol and mixed with a 40% wt dimethylamine in water (180 uL, 1.6 mmol) and stirred overnight. Solvent and excess reagents were evaporated. The oily residue was taken up in ethylacetate, washed with saturated sodium bicarbonate, brine and dried over sodium sulfate. The product N-[3-[[(butylamino)-sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[[2-(dimethylamino)-1-oxoethyl]amino]3,3-dimethylbutanamide was purified by silica gel chromatography. Anal. Calc'd for C28H51N5O5S. 0.5H2O: C, 58.10; H, 9.06; N, 12.09. Found: C, 57.81; H, 8.44; N, 12.01. EI MS M+=569.
EXAMPLE 15




Preparation of N1-[2R-hydroxy-3-[[(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide
Part A:
A solution of the carbamate from Example 7 (412 mg, 0.77 mmoles) containing 20 mL methanol and 5 mL acetic acid was hydrogenated over 10% palladium on carbon (80 mg) for 6 h. After filtration of the reaction mixture, the filtrate was evaporated to an oil. The oily residue was dissolved in ethyl acetate and washed with sodium bicarbonate solution. The organic layer was evaporated to give the free amine (100 mg).
Part B:
The free amine from Part A (80 mg, 0.20 mmoles) was coupled with N-BOC-L-asparagine (61 mg, 0.264 mmoles) in the presence of N-hydroxybenzotriazole (48 mg, 0.35 mmoles) and EDC (50 mg, 0.264 mmoles) to yield 125 mg of N1 [2R-hydroxy-3-[3-[(4-methyl-1-piperaziny)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butane diamide.
Part C:
N1[2R-hydroxy-3-[3-[(4-methyl-1-piperaziny)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butane diamide (118 mg, 0.19 mmole) was stirred in 4N HCl in dioxane (5 mL) at r.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness. The product was dried in vacuo. This material (116 mg, 0.19 mmoles) was then reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester (53 mg, 0.19 mmoles), DIEA (83 uL, 0.60 mmoles) in DMF (1 mL) overnight. The product N1-[2R-hydroxy-3-[(4-methyl-1-piperazinyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-((2-quinolinylcarbonyl)amino]butanediamid was purified by silica gel chromatography. Anal. Calcd for C33H45N7O6S. 0.5H2O/0.3 CH3CH2OCH2CH3: C, 58.76; H, 7.06; N, 14.03. Found: C, 58.23; H, 6.98; N, 13.81.
EXAMPLE 16




Preparation of N1-[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide
Part A:
The procedures described in Example 6, Parts A–C, were used to prepare phenylmethyl[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]carbamate. A methanolic solution of this carbamate (460 mg, 0.796 mmoles) was hydrogenated over 10% palladium on carbon (90 mg) to give the free amine (329 mg).
Part B:
The free amine from Part A (266 mg, 0.6 mmoles) was coupled with N-BOC-L-asparagine (167 mg, 0.72 mmoles) in the presence of N-hydroxybenzotriazole (130 mg, 0.96 mmoles) and EDC (138 mg, 0.72 mmoles) to yield 306 mg of N1[2R-hydroxy-3-[3-[(butylamino)sulfonyl]2-methylpropyl)amino]-1S-(phenylmethyl propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino)butane diamide after purification on a silica column.
Part C:
N1[2R-hydroxy-3-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-1s-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butane diamide (150 mg, 0.26 mmoles) was stirred in 4N HCl in dioxane (4 mL) at r.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness. The product was dried in vacuo. This material (140 mg, 0.26 mmoles) was then reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester (70 mg, 0.26 mmoles), DIEA (72 uL, 0.52 mmoles) in dichloromethane (2 mL) overnight. The product -N1-[3-[[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-25-[(2-quinolinylcarbonyl)amino]butanediamide was purified by silica gel chromatography. Anal. Calcd for C32H44N6O6S: C, 59.98; H, 6.92; N, 13.12. Found: C, 59.98; H, 6.65; N, 12.72.
EXAMPLE 17




Preparation of N1-[3[-[[(1,1-dimethylehtyll)amino]sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide
Part A:
A 20 mL methanol solution of phenylmethyl[2R-hydroxy 3-[[(1,1-dimethylethyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]carbamate from Example 8 (170 mg, 0.33 mmoles) was hydrogenated over 10% palladium on carbon (40 mg). The resulting free amine (110 mg, 0.30 mmole) was coupled with N-BOC-L-asparagine (84 mg, 0.36 mmoles) in the presence of N-hydroxybenzotriazole (65 mg, 0.48 mmoles) and EDC (69 mg, 0.36 mmoles) to yield 160 mg of N1[2R-hydroxy-3-[3-[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-1s-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butane diamide.
Part B:
N1[2R-hydroxy-3-[3[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]]-2S-[(1,1-dimethylethoxycarbonyl)amino]butane diamide (150 mg, 0.25 mmole) was stirred in 4N HCl in dioxane (5 mL, at r.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness. The product was dried in vacuo. This material (135 mg, 0.25 mmoles) was then reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester (70 mg, 0.25 mmoles), DIEA (72 uL, 0.52 mmoles) in DMF (1 mL) overnight. The product N1-(3[-[[(1,1-dimethylehtyl)amino)sulfonyl].(2-methylpropyl)amino]-2R-hydroxy-1s-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide was purified by silica gel chromatography (85 mg, 53%). Anal. Calcd for C32H44N6O6S. 0.8H2O: C, 58.66; H, 7.02; N, 2.83. Found: C, 59.00; H, 6.84; N, 12.54.
EXAMPLE 18




Preparation of N′-[3-[[(N,N-dimethylamino)sulfonyl](3-methylbutyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide
Part A:
Preparation of N-3(S)-(Benzyloxycarbonyl)-amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl). A solution of 20 g (67 mmol) of N-benzyloxycarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane in 140 mL of isopropyl alcohol was treated with 83 g (952 mmol) of isoamylamine and refluxed for one hour. The solution was cooled, concentrated, hexane added and the resulting solid filtered to afford 22.4 g of the desired product.
Part B:
Preparation of N-3(S)-(Benzyloxycarbonyl)-amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl)-N-(t-butyloxycarbonyl). To a solution of 22.4 g (58.3 mmol) of product from Part A above, 6.48 g (64.1 mmol) of triethylamine and 150 mg of N,N-dimethyl-4-aminopyridine in 200 mL of tetrahydrofuran at 0° C. was added 12.7 g (58.3 mmol) of di-t-butylpyrocarbonate in 10 mL of THF. After 3.5 hours at room temperature, the volatiles were removed, ethyl acetate added and washed with 5% citric acid, sat'd NaHCO3, dried and concentrated to afford 30 g of crude product. Chromatography on silica gel using 20% ethyl acetate/hexane afforded 22.5 g (79%) of the desired product.
Part C:
Preparation of N-3(S)-[N-benzyloxycarbonyl-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl)-N-(t-butyloxycarbonyl). A solution of 22.5 g of product from Part B above in 200 mL of ethanol was hydrogenated over 5.9 g of 10% palladium-on-carbon under 50 psig hydrogen for one hour. The catalyst was filtered and the solvent removed under reduced pressure to afford 15.7 g of free amine. This was dissolved in 130 mL of DMF and 4.54 g (44.9 mmol) of N-methylmorpholine an added to a mixture of 13.3 g (49.9 mmol) N-benzyloxy-carbonyl-L-asparagine, 11.5 g (74.9 mmol) of N-hydroxybenzotriazole and 10.5 g (54.9 mmol) of EDCl in 120 mL of DMF at 0° C., which had been preactivated for one hour prior to the addition. The mixture was stirred for 2 hours at 0° C. and then for 12 hours at room temperature. The reaction was poured into 1 L of sat'd aqueous sodium bicarbonate, the solid collected, dissolved in ethyl acetate, washed with water, sat'd sodium bicarbonate, 5% citric acid and brine, dried and concentrated to afford 16.7 g of the desired product.
Part D:
Preparation of N-3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl)-N-(t-butyloxycarbonyl). A solution of 16.7 g (28.0 mmol) of product from Part C in 250 mL of methanol was hydrogenated over 6.0 g of 10% palladium-on-carbon and under 50 psig hydrogen for one hour. The catalyst was filtered and the solution concentrated to afford 10.0 g of free amine. This was dissolved in 100 mL of methylene chloride, 4.35 g (43 mmol) of N-methylmorpholine was added followed by 5.53 g (20.5 mmol) of quinoline-2-carboxylic acid, N-hydroxysuccinimide ester. This was stirred at room temperature overnight, the solvent removed, ethyl acetate added and washed with 5% citric acid, sat'd sodium bicarbonate, brine, dried and concentrated to afford 14 g of crude product. Recrystallization from ethyl acetate and hexane afforded 10.5 g (83%) of desired product.
Part E:
Preparation of N-3(S)-[N-(2-quinolinyl-carbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl). To 80 mL of 4N hydrochloric acid in dioxane was added 9.17 g (14.8 mmol) of product from Part D above. After one hour, the product becomes gummy. The solvents were removed, diethyl ether added and removed and the residue dissolved in 20 mL of methanol. This solution was added to 400 mL of sat'd aqueous sodium bicarbonate, the solids collected, washed with acetone and hexane and dried in vacuo over P2O5 to afford 4.75 g of the desired product.
Part F:
To a solution of 200 mg (0.38 mmol) of the amino alcohol from Part E above in 10 mL of anhydrons tetrahydrofuran and 0.3 mL of N,N-dimethylformamide, was added 42 mg (0.42 mmol) of triethylamine and then 55 mg (0.38 mmol) of dimethylsulfamoyl chloride. After stirring from twenty hours at room temperature, the volatiles were removed in vacuo, ethyl acetate added and the solution washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate and saturated brine. The organic layer was dried and concentrated to afford 166 mg of crude product, which was chromatographed on silica gel using a gradient of 1–10% isopropanol in methylene chloride to afford 119 mg of pure product, m/e 627 (M+H). Calcd. for C31H42N6O6S 627.2965. found 627.2998.
EXAMPLE 19




Preparation of [(4-methoxyphenyl)methyl][3-[[3-[[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]amino]-2R-methyl-3-oxopropyl]carbamate
To a solution of 83 mg (0.31 mmol) of N-(4-methoxy)benzyloxycarbonyl 2R-methyl-3-aminopropionic acid and 71 mg (0.46 mmol) of N-hydroxybenzotriazole in 2 mL C, anhydrous N,N-dimethylformamide (DM-F at 0° C., was added 65 mg (0.34 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After two hours at 0° C., a solution of 104 mg (0.28 mmol) of free amine from example 8, part C in 0.5 mL of DMF was added. After two hours at 0° C. and fourteen hours at room temperature, the DMF was removed in vacuo, ethyl acetate added, washed with saturated aqueous sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and concentrated to afford 200 mg of crude material. This was chromatographed on silica gel using 3% methanol/methylene chloride to afford 120 mg of product, which was further purified by crystallization from diethyl ether/hexane to afford 25 mg (13%) of the desired product m/e=627 (M+Li).
EXAMPLE 20




Preparation of N4-[3-[[[(1,1-dimethylethyl)amino]-sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S -(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)-amino]butanediamide
107 mg (0.37 mmol) of N-2-(quinoylcarbonyl)-L-isoasparagine and 76 mg (1.5 ea) of N-hydroxysuccinamide were dissolved in 2 mL of dimethylformamide and cooled to zero degrees C. To this was added 111 mg (0.37 mmol) of EDC and the solution stirred for 20 minutes. To this cooled solution was added 140 mg 10.37 mmol) of the free amine from example 8, part C and the reaction was returned to room temperature and stirred for 18 hours. The dimethylformamide was removed by evaporation and the residue was partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with 5% KHSO4 and brine, dried over magnesium sulfate, filtered and concentrated to yield 216 mg of crude solid, which was chromatographed using ethyl acetate:methanol:hexane, 95:5:50 to yield 110 mg (4.8% yield) of pure product, m/e=641 (M+H).
EXAMPLE 21
Following the procedures of Examples 1–20, the compounds shown in Tables 3A and 3B were prepared.







TABLE 3A













 












Entry







No.
R
R1
R3
R4
R5















1
Cbz
t-Butyl
i-Amyl
Methyl
Methyl


2
Q
t-Butyl
i-Amyl
Methyl
Methyl


3
Cbz
i-Butyl
i-Butyl
Methyl
Hydrogen


4
N,N-Dimethylglycine
t-Butyl
i-Butyl
n-Butyl
Hydrogen


5
N,N-Dimethylglycine
t-Butyl
i-Butyl
Methyl
Hydrogen


6
Q
CH2C(O)NH2
i-Butyl
n-Butyl
Hydrogen


7
Q
CH2C(O)NH2
i-Butyl
t-Butyl
Hydrogen


 


8
Q
CH2C(O)NH2
i-Butyl






 


9
Q
CH2C(O)NH2
i-Butyl
Phenyl
Hydrogen


10
Q
CH2C(O)NH2
i-Butyl
Cyclohexyl
Hydrogen
















TABLE 3B













 












Entry
R
R1
R3
R4
R5





A
Cbz
t-butyl
isoamyl
methyl
methyl


B
Cbz
t-butyl
isobutyl
methyl
H


C
N,N-Dimethylglycine
t-butyl
isobutyl
methyl
H


D
Q
CH2CONH2
isobutyl
cyclohexyl
H


E
Q
CH2CONH2
isobutyl
phenyl
H


 


F
N,N-Dimethylglycine
t-butyl
isobutyl
NR4R5 =













Utilizing the procedures set forth above, the compounds shown in Tables 4–14 could be prepared. Thus, utilizing the intermediates of Examples 1–10 according to the procedures in Examples 14–21, the compounds shown in Tables 4–16 could be prepared.







TABLE 4













 











Entry






No.
R
R3
R4
R5














1
Cbza
CH3
n-Butyl
CH3


2
Cbz
i-Butyl
CH3
C6H5


3
Cbz
i-Butyl
n-Butyl
H


4
Qb
i-Butyl
n-Butyl
H


5
Cbz
i-Propyl
n-Butyl
H


6
Q
i-Propyl
n-Butyl
CH3


7
Cbz
C6H5
n-Butyl
H


 


8
Cbz




n-Butyl
H


 


9
Cbz




n-Butyl
H


 


10
Q




n-Butyl
H


 


11
Cbz




n-Butyl
H


 


12
Cbz
i-Butyl
n-Propyl
H


13
Cbz
i-Butyl
—CH2CH(CH3)2
H


 


14
Cbz




n-Butyl
H


 


15
Cbz




i-Propyl
H


 


16
Cbz




—CH2CH2CH(CH3)2
H


 


17
Cbz
i-Butyl
—CH2CH3
H


18
Cbz
i-Butyl
—CH(CH3)2
H


 


19
Cbz
i-Butyl




H


 


20
Q
n-Butyl




H


 


21
Cbz




—(CH2)2CH(CH3)2
H


 


22
Cbz
(CH2)2CH(CH3)2
—CH(CH3)2
H


23
Q
i-Butyl
—CH(CH3)2
H


24
Cbz
i-Butyl
—C(CH3)3
H


25
Q
i-Butyl
—C(CH3)3
H


 


26
Cbz




—C(CH3)3
H


 


27
Q




—C(CH3)3
H


 


28
Cbz
—(CH2)2CH(CH3)2
—C(CH3)3
CH3


29
Q
—(CH2)2CH(CH3)2
—C(CH3)3
CH3


30
Cbz
—CH2C6H5
—C(CH3)3
H


31
Q
—CH2C6H5
—C(CH3)3
H


32
Cbz
—(CH2)2C6H5
—C(CH3)3
CH3


33
Cbz
—(CH2)2C6H5
—C(CH3)3
H


34
Cbz
n-Butyl
—C(CH3)3
H


35
Cbz
n-Pentyl
—C(CH3)3
H


36
Cbz
n-Hexyl
—C(CH3)3
H


 


37
Cbz




—C(CH3)3
H


 


38
Cbz
—CH2C(CH3)3
—C(CH3)3
H


39
Q
—CH2C(CH3)3
—C(CH3)3
H


 


40
Cbz




—C(CH3)3
H


 


41
Cbz
—CH2C6H5OCH3(para)
—C(CH3)3
H


 


42
Cbz




—C(CH3)3
H


 


43
Cbz




—C(CH3)3
H


 


44
Cbz
—(CH2)2C(CH3)3
—C(CH3)3
H


45
Q
—(CH2)2C(CH3)3
—C(CH3)3
H


46
Cbz
—(CH2)4OH
—C(CH3)3
H


47
Q
—(CH2)5OH
—C(CH3)3
H


 


48
Q




—C(CH3)3
H


 


49
Q




—C(CH3)3
H


 


50
Cbz
—CH2CH(CH3)2
—C6H5
H


 


51




—CH2CH(CH3)2
—C6H5
Me


 


52




—CH2CH(CH3)2
—C6H5
H


 


53




—CH2CH(CH3)2
—C6H5
H


 


54




—CH2CH(CH3)2
—C6H5
H


 


55




—CH2CH(CH3)2
—C6H5
Me


 


56




—CH2CH(CH3)2
—C6H5
H


 


57




—CH2CH(CH3)2
—C6H5
Me


 


58




—CH2CH(CH3)2
—C6H5
Me


 


59




—CH2CH(CH3)2
—C6H5
H


 


60




—CH2CH(CH3)2
—C6H5
Me


 


61




—CH2CH(CH3)2
—C6H5
H


 


62




—CH2CH(CH3)2
—C6H5
H


 


63




—CH2CH(CH3)2
—C6H5
H


 


64




—CH2CH(CH3)2
—C6H5
Me


 


65




—CH2CH(CH3)2
—C6H5
H


 


66




—CH2CH(CH3)2
—C6H5
H


 


67




—CH2CH(CH3)2
—C6H5
H


 


68




—CH2CH(CH3)2
—C6H5
H


 


69




—CH2CH(CH3)2
—C6H5
H


 


70
Q
—CH2Ph
-Ph
H


 


71
Q




-Ph
H


 


72
Q




-Ph
H


 


73
Q




-Ph
H


 


74
Q




-Ph
H


 


75
Q




-Ph
H


 


76
Q
—CH2CH═CH2
-Ph
H


 


77
Q




-Ph
H


 


78
Q




-Ph
H


 


79
Q
—CH2CH2Ph
-Ph
H


80
Q
—CH2CH2CH2CH2OH
-Ph
H


81
Q
—CH2CH2N(CH3)2
-Ph
H


 


82
Q




-Ph
H


 


83
Q
—CH3
-Ph
H


84
Q
—CH2CH2CH2SCH3
-Ph
H


85
Q
—CH2CH2CH2S(O)2CH3
-Ph
H


 


86
Q
—CH2CH2CH2CH(CH3)2




H


 


87
Q
—CH2CH2CH(CH3)2




H


 


88
Q
—CH2CH2CH(CH3)2
—CH2CH2CH3
H


89
Q
—CH2CH2CH2CH(CH3)2
—CH3
H


 


90
Q
—CH2CH2CH(CH3)2




H


 


91
Q
—CH2CH2CH(CH3)2




H


 


92
Q
—CH2CH2CH(CH3)2




H


 


93
Q
—CH2CH2CH(CH3)2




H


 


94
Q
—CH2CH2CH(CH3)2




H


 


95
Q
—CH2CH2CH(CH3)2




H


 


96
Q
—CH2CH2CH(CH3)2




H


 


97
Q
—CH2CH2CH(CH3)2




H


 


98
Q
—CH2CH2CH(CH3)2




H


 


99
Q
—CH2CH2CH(CH3)2




H


 


100
Q
—CH2CH2CH(CH3)2




H


 


101
Q
—CH2CH2CH(CH3)2






 


102
Q
—CH2CH2CH(CH3)2




H


 


103
Q
—CH2CH(CH3)2




H


 


104
Q
—CH2CH(CH3)2




H


 


105
Q
—CH2CH(CH3)2




H


 


106
Q
—CH2CH2CH3




H


 


107
Q
—CH2CH2CH2CH3




H


 


108
Q
—CH2CH2CH3




H


 


109
Q
—CH2CH2CH3




H


 


110
Q
—CH2CH2CH3




H


 


111
Q
—CH2CH2CH3




H





abenzyloxycarbonyl


b2-quinolinylcarbonyl













TABLE 5













 










Entry





No.
A
R3
R4













1
Cbz-Val.
i-amyl
—C6H5


2
Cbz-Leu
i-amyl
—C6H5


3
Cbz-Ile
i-amyl
—C6H5


4
Ac-D-homo-Phe
i-Bu
methyl


 


5
Qui-Orn(g-Cbz)




—C6H5


 


6
Cbz-Asn
—CH2CH═CH2
—C6H5


 


7
Acetyl-t-BuGly
i-amyl
—C6H5


8
Acetyl-Phe
i-amyl
—C6H5


9
Acetyl-Ile
i-amyl
—C6H5


10
Acetyl-Leu
i-amyl
—C6H5


11
Acetyl-His
i-amyl
—C6H5


12
Acetyl-Thr
i-amyl
—C6H5


13
Acetyl-NHCH(C(CH3)2(SCH3))C(O)—
i-amyl
—C6H5


14
Cbz-Asn
i-amyl
—C6H5


15
Cbz-Ala
i-amyl
—C6H5


16
(N,N-dimethylglycinyl)Val
i-amyl
—C6H5


17
(N-methylglycinyl)Val
i-amyl
—C6H5


18
(N,N-dimethylglycinyl)Ile
i-amyl
—C6H5


19
(N-methylglycinyl)Ile
i-amyl
—C6H5


20
(N,N-dimethylglycinyl)Val
i-butyl
n-butyl


21
(N,N-dimethylglycinyl)Val
i-amyl
n-butyl


 


22
(N,N-dimethylglycinyl)Val




n-butyl


 


23
(N,N-dimethylglycinyl)Val




n-butyl


 


24
(N,N-dimethylglycinyl)Ile
i-butyl
n-butyl


25
(N,N-dimethylglycinyl)Ile
i-amyl
n-butyl


 


26
(N,N-dimethylglycinyl)Ile




n-butyl


 


27
(N,N-dimethylglycinyl)Ile




n-butyl


 


20
Cbz-Ala
i-amyl
—C6H5


21
Cbz-beta-cyanoAla
i-amyl
—C6H5


22
Cbz-t-BuGly
i-amyl
—C6H5


23
Q-t-BuGly
i-amyl
—C6H5


24
Q-SCH3Cys
i-amyl
—C6H5


25
Cbz-SCH3Cys
i-amyl
—C6H5


26
Q-Asp
i-amyl
—C6H5


27
Cbz-(NHCH(C(CH3)2(SCH3))C(O)—
i-amyl
—C6H5


28
Cbz-EtGly
i-amyl
—C6H5


29
Cbz-PrGly
i-amyl
—C6H5


30
Cbz-Thr
i-amyl
—C6H5


31
Q-Phe
i-amyl
—C6H5


32
Cbz-Phe
i-amyl
—C6H5


33
(N,N-dimethylglycinyl)Val
i-butyl
t-butyl


34
(N,N-dimethylglycinyl)Val
i-amyl
t-butyl


 


35
(N,N-dimethylglycinyl)Val




t-butyl


 


36
(N,N-dimethylglycinyl)Val




t-butyl


 


37
(N,N-dimethylglycinyl)Ile
i-butyl
t-butyl


38
(N,N-dimethylglycinyl)Iie
i-amyl
t-butyl


 


39
(N,N-dimethylglycinyl)Ile




t-butyl


 


40
(N,N-dimethylglycinyl)Ile




t-butyl
















TABLE 6













 









Entry
R1
R4












1
CH2SO2CH3
t-butyl


2
(R)-CH(OH)CH3
t-butyl


3
CH(CH3)2
t-butyl


4
(R,S)CH2SOCH3
t-butyl


5
CH2SO2NH2
t-butyl


6
CH2SCH3
t-butyl


7
CH2CH(CH3)2
t-butyl


8
CH2CH2C(O)NH2
t-butyl


9
(S)-CH(OH)CH3
t-butyl


10
—CH2C≡C—H
t-butyl
















TABLE 7













 










Entry
R2
A
R4













1
n-Bu
Cbz-Asn
t-butyl


2
cyclohexylmethyl
Cbz-Asn
t-butyl


3
n-Bu
Boc
t-butyl


4
n-Bu
Cbz
t-butyl


5
C6H5CH2
Boc
t-butyl


6
P—F—C6H5CH2
Cbz
t-butyl


7
C6H5CH2
benzoyl
t-butyl


8
cyclohexylmethyl
Cbz
t-butyl


9
n-Bu
Q-Asn
t-butyl


10
cyclohexylmethyl
Q-Asn
t-butyl


11
C6H5CH2
Cbz-Ile
t-butyl


12
C6H5CH2
Q-Ile
t-butyl


13
P—F—C6H5CH2
Cbz-t-BuGly
t-butyl


14
C6H5CH2
Q-t-BuGly
t-butyl


15
C6H5CH2
Cbz-Val
t-butyl


16
C6H5CH2
Q-Val
t-butyl


17
2-naphthylmethyl
Cbz-Asn
t-butyl


18
2-naphthylmethyl
Q-Asn
t-butyl


19
2-naphthylmethyl
Cbz
t-butyl


20
n-Bu
Cbz-Val
t-butyl


21
n-Bu
Q-Val
t-butyl


22
n-Bu
Q-Ile
t-butyl


23
n-Bu
Cbz-t-BuGly
t-butyl


24
n-Bu
Q-t-BuGly
t-butyl


25
p-F(C6H4)CH2
Q-Asn
t-butyl


26
P-F(C6H4)CH2
Cbz
t-butyl


27
p-F(C6H4)CH2
Cbz-Asn
t-butyl


28
C6H5CH2
Cbz-propargylglycine
t-butyl


29
C6H5CH2
Q-propargylglycine
t-butyl


30
C6H5CH2
acetylpropargylglycine
t-butyl
















TABLE 8













 









Entry
R3
R4





1
—CH2CH(CH3)2
—C(CH3)2


 


2
—CH2CH2CH(CH3)2






 


3
—CH2CH2CH(CH3)2






 


4
—CH2CH2CH(CH3)2






 


5
—CH2CH2CH(CH3)2




















TABLE 9













 









Entry
R
R1












1




—CH3


 


2




—CH3


 


3




—CH(CH3)2


 


4




—CH(CH3)2


 


5




—C(CH3)3


 


6




—CH3


 


7




—CH3


 


8




—CH3


 


9




—CH3


 


10




—CH3


 


11




—CH3


 


12




—CH3


 


13




—CH3


 


14




—CH3


 


15




—CH3


 


16




—CH3


 


17




—CH3


 


18






 


19




















TABLE 10













 











Entry
R1
R1′
R1′′
R





1
H
H
H






 


2
H
H
H






 


3
H
CH3
H






 


4
H
CH3
CH3






 


5
H
H
CO2CH3






 


6
H
H
H






 


7
H
H
H






 


8
H
H
CONH2
Cbz


9
H
H
CONH2
2-quinolinylcarbonyl
















TABLE 11













 










Entry
R
R′
X





1
R = H
R′ = H
X = H


2
R = Me
R′ = Me
X = H


3
R = H
R′ = Me
X = H


4
R = Me
R′ = Me
X = F


5
R = H
R′ = Me
X = F


6
R = Cbz
R′ = Me
X = H


7
R = H
R′ = Bz
X = H


8
R + R′ = pyrrole
X = H
















TABLE 12













 








Entry
Acyl Group (R)











1
benzyloxycarbonyl


2
tert-butoxycarbonyl


3
acetyl


4
2-quinoylcarbonyl


5
phenoxyacetyl


6
benzoyl


7
methyloxaloyl


8
pivaloyl


9
trifluoracetyl


10
bromoacetyl


11
hydroxyacetyl


12
morpholinylacetyl


13
N,N-dimethylaminoacetyl


14
N-benzylaminoacetyl


15
N-phenylaminoacetyl


16
N-benzyl-N-methylaminoacetyl


17
N-methyl-N-(2-hydroxyethyl)aminoacetyl


18
N-methylcarbamoyl


19
3-methylbutyryl


20
N-isobutylcarbamoyl


21
succinoyl (3-carboxypropionyl)


22
carbamoyl


23
N-(2-indanyl)aminoacetyl


24
N-methylaminoacetyl
















TABLE 13













 









Entry
R3
R4












1
—CH3
-n-Butyl


2
-n-Butyl
—CH3


3
-i-Butyl
-n-Butyl


4
-i-Propyl
-n-Butyl


5
—C6H5
-n-Butyl


 


6




-n-Butyl


 


7




-n-Butyl


 


8




-n-Butyl


 


9
-i-Butyl
-n-Propyl


10
-i-Butyl
—CH2CH(CH3)2


 


11




-n-Butyl


 


12




-i-Propyl


 


13




—CH2CH2CH(CH3)2


 


14
i-Butyl
—CH2CH3


15
i-Butyl
—CH(CH3)2


 


16
i-Butyl






 


17




—(CH2)2CH(CH3)2


 


18
(CH2)2CH(CH3)2
—CH(CH3)2


19
i-Butyl
—CH(CH3)2


20
i-Butyl
—C(CH3)3


 


21




—C(CH3)3


 


22
—(CH2)2CH(CH3)2
—C(CH3)3


23
—CH2C6H5
—C(CH3)3


24
—(CH2)2C6H5
—C(CH3)3


25
n-Butyl
—C(CH3)3


26
n-Pentyl
—C(CH3)3


27
n-Hexyl
—C(CH3)3


 


28




—C(CH3)3


 


29
—CH2C(CH3)3
—C(CH3)3


 


30




—C(CH3)3


 


31
—CH2C6H5OCH3(para)
—C(CH3)2


 


32




—C(CH3)3


 


33




—C(CH3)3


 


34
—(CH2)2C(CH3)3
—C(CH3)3


35
—(CH2)4OH
—C(CH3)3


 


36




—C(CH3)3


 


37




—C(CH3)3


 


38
—CH2CH(CH3)2
—C6H5


39
i-amyl
—CH2C(CH3)3


 


40




—CH2C(CH3)3


 


41




—CH2C(CH3)3


 


42
i-butyl
—CH2C(CH3)3


43
—CH2Ph
-Ph


 


44




-Ph


 


45




-Ph


 


46




-Ph


 


47




-Ph


 


48




-Ph


 


49
—CH2CH═CH2
-Ph


 


50




-Ph


 


51




-Ph


 


52
—CH2CH2Ph
-Ph


53
—CH2CH2CH2CH2OH
-Ph


54
—CH2CH2N(CH3)2
-Ph


 


55




-Ph


 


56
—CH3
-Ph


57
—CH2CH2CH2SCH3
-Ph


58
—CH2CH2CH2S(O)2CH3
-Ph


 


59
—CH2CH2CH(CH3)2






 


60
—CH2CH2CH(CH3)2






 


61
—CH2CH2CH(CH3)2
—CH2CH2CH3


62
—CH2CH2CH(CH3)2
—CH3


 


63
—CH2CH2CH(CH3)2






 


64
—CH2CH2CH(CH3)2






 


65
—CH2CH2CH(CH3)2






 


66
—CH2CH2CH(CH3)2






 


67
—CH2CH2CH(CH3)2






 


68
—CH2CH2CH(CH3)2






 


69
—CH2CH2CH(CH3)2






 


70
—CH2CH2CH(CH3)2






 


71
—CH2CH2CH(CH3)2






 


72
—CH2CH2CH(CH3)2






 


73
—CH2CH2CH(CH3)2






 


74
—CH2CH2CH(CH3)2






 


75
—CH2CH(CH3)2






 


76
—CH2CH(CH3)2






 


77
—CH2CH(CH3)2






 


78
—CH2CH(CH3)2






 


79
—CH2CH2CH3






 


80
—CH2CH2CH2CH3






 


81
i-butyl
t-butyl


82
i-amyl
t-butyl


 


83




t-butyl


 


84




t-butyl


 


85
i-butyl









abenzyloxycarbonyl


b2-quinolinylcarbonyl













TABLE 14













 









Entry
R1
R3





1
C(CH3)3
CH2CH2CH(CH3)2


2
CH2C≡CH
CH2CH2CH(CH3)2


3
C(CH3)2(SCH3)
CH2CH2CH(CH3)2


4
C(CH3)2(S[O]CH3)
CH2CH2CH(CH3)2


5
C(CH3)2(S[O]2CH3)
CH2CH2CH(CH3)2


6
C(CH3)3
CH2CH(CH3)2


 


7
C(CH3)3






 


8
CH(CH3)2
CH2CH(CH3)2


9
CH(CH2CH3)(CH3)
CH2CH(CH3)2
















TABLE 15













 










R3











—CH2CH(CH3)2
—N(CH3)2



—CH2CH(CH3)2
—N(CH2CH3)2



—CH2CH(CH3)2
—N(CH(CH3)2)2



—CH2CH2CH(CH3)2
—N(CH3)2



—CH2CH2CH(CH3)2
—N(CH2CH3)2



 



—CH2CH2CH(CH3)2







 







—N(CH3)2—N(CH2CH3)2



 



—CH2CH2CH(CH3)2







 



—CH2CH2CH(CH3)2







 














 














 







N(CH3)(t-Bu)



 














 














 














 














 



—CH2CH(CH3)2







 



—CH2CH(CH3)2







 



—CH2CH(CH3)2





















TABLE 16













 










R3











—CH2CH(CH3)2
—N(CH3)2



—CH2CH(CH3)2
—N(CH2CH3)2



—CH2CH(CH3)2
—N(CH(CH3)2)2



—CH2CH2CH(CH3)2
—N(CH3)2



—CH2CH2CH(CH3)2
—N(CH2CH3)2



 



—CH2CH2CH(CH3)2







 







—N(CH3)2—N(CH2CH3)2



 














 














 







N(CH3)(t-Bu)



 














 














 














 














 



—CH2CH(CH3)2







 



—CH2CH(CH3)2







 



—CH2CH(CH3)2














EXAMPLE 22
The compounds of the present invention are effective HIV protease inhibitors. Utilizing an enzyme assay as described below, the compounds set forth in the examples herein disclosed inhibited the HIV enzyme. The preferred compounds of the present invention and their calculated IC50 (inhibiting concentration 50%, i.e., the concentration at which the inhibitor compound reduces enzyme activity by 50%) values are shown in Table 17. The enzyme method is described below. The substrate is 2-Ile-Nle-Phe(p-NO2)-Gln-ArgNH2. The positive control is MVT-101 (Miller, M. et al, Science, 246, 1149 (1989)]The assay conditions are as follows:

    Assay buffer: 20 mM sodium phosphate, pH 0.4
    
        20% glycerol
        1 mM EDTA
        1 mM DTT
        0.1% CHAPS
    
    


The above described substrate is dissolved in DMSO, then diluted 10 fold in assay buffer. Final substrate concentration in the assay is 80 μM.
HIV protease is diluted in the assay buffer to a final enzyme concentration of 12.3 nanomolar, based on a molecular weight of 10,780.
The final concentration of DMSO is 14% and the final concentration of glycerol is 18%. The test compound is dissolved in DMSO and diluted in DMSO to 10× the test concentration; 10 μl of the enzyme preparation is added, the materials mixed and then the mixture is incubated at ambient temperature for 15 minutes. The enzyme reaction is initiated by the addition of 40 μl of substrate. The increase in fluorescence is monitored at 4 time points (0, 8, 16 and 24 minutes) at ambient temperature. Each assay is carried out in duplicate wells.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.









TABLE 17





Entry
Compound
IC50 (nanomolar)

















1




40


 


2




5


 


3




3


 


4




2


 


5




13









EXAMPLE 23
The effectiveness of the compounds listed in Table 17 were determined in the above-described enzyme assay and in a CEM cell assay.
The HIV inhibition assay method of acutely infected cells is an automated tetrazolium based calorimetric assay essentially that reported by Pauwles et al, J. Virol. Methods, 20, 309–321 (1988). Assays were performed in 96-well tissue culture plates. CEM cells, a CD4+ cell line, were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetal calf serum and were then treated with polybrene (2 μg/ml). An 80 μl volume of medium containing 1×104 cells was dispensed into each well of the tissue culture plate, no each well was added a 100 μl volume of test compound dissolved in tissue culture medium (or medium without test compound as a control) to achieve the desires final concentration and the cells were incubated at 37° C. for 1 hour. A Frozen culture c. HIV-1 was diluted in culture medium to a concentration of 5×104 TCID50 per ml (TCID50=the dose of virus that infects 50% of cells in tissue culture), and a 20 μL volume of the virus sample (containing 1000 TCID50 of virus) was added to wells containing test compound and to wells containing only medium (infected control cells). Several wells received culture medium without virus (uninfected control cells). Likewise, the intrinsic toxicity of the test compound was determined by adding medium without virus to several wells containing test compound. In summary, the tissue culture plates contained the following experiments:
















Virus
Cells
Drug









1.
+
−
−



2.
+
+
−



3.
+
−
+



4.
+
+
+










In experiments 2 and 4 the final concentrations of test compounds were 1, 10, 100 and 500 μg/ml. Either azidothymidine (AZT) or dideoxyinosine (ddI) was included as a positive drug control. Test compounds were dissolved in DMSO and diluted into-tissue culture medium so that the final DMSO concentration did not exceed 1.5% in any case. DMSO was added to all control wells at an appropriate concentration.
Following the addition of virus, cells were incubated at 37° C. in a humidified, 5% CO2 atmosphere for 7 days. Test compounds could be added on days 0, 2 and 5 if desired. On day 7, post-infection, the cells in each well were resuspended and a 100 μl sample of each cell suspension was removed for assay. A 20 μL volume of a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each 100L cell suspension, and the cells were incubated for 4 hours at 27° C. in a 5% CO2 environment. During this incubation, MTT is metabolically reduced by living cells resulting in the production in the cell of a colored formazan product. To each sample was added 100 μl of 10% sodium dodecylsulfate in 0.01 N HCl to lyse the cells, and samples were incubated overnight. The absorbance at 590 nm was determined for each sample using a Molecular Devices microplate reader. Absorbance values for each set of wells is compared to assess viral control infection, uninfected control cell response as well as test compound by cytotoxicity and antiviral efficacy.
The biological data shown in Tables 18 and 19 were obtained from the compounds shown in Tables 1C and 3B, respectively.












TABLE 18







Entry
IC50 or





Table 1C
% Inhibition
EC50
TD50






















A
29% @ 0.1
uM





B
55% @ 10.0
uM



C
59% @ 1.0
uM



D
29% @ 0.1
uM



E
70
nM
880 nM
7.5 uM



F
22% @ 0.1
uM



G
66
nM



H
48% @ 10.0
uM



I
1.7
uM



J
2.69
uM



K
60% @ 1.0
uM



L
38% @ 10.0
uM






















TABLE 19







Entry






Table 3B
IC50 (nM)
EC50 (nM)
TD50 (μM)





















A
20





B
27



C
42
350
>100



D
4.4
27
289



E
4.0
13
8.3



F
6.6
17
77





















TABLE 20





Entry
Compound
IC50 (nm)
EC50 (nm)
TD50 (nm)



















1




40
167
56,000


 


2




5
23
65,000


 


3




3
42
28,000


 


4




2
<15
39,000









The compounds of the present invention are effective antiviral compounds and, in particular, are effective retroviral inhibitors as shown above. Thus, the subject compounds are effective HIV protease inhibitors. It is contemplated that the subject compounds will also inhibit other retroviruses such as other lentiviruses in particular other strains of HIV, e.g. HIV-2, human T-cell leukemia virus, respiratory syncitial virus, simia immunodeficiency virus, feline leukemia virus, feline immuno-deficiency virus, hepadnavirus, cytomegalovirus and picornavirus. Thus, the subject compounds are effective in the treatment and/or proplylaxis of retroviral infections.
Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltarcaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of Formula I with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free aced, a free base, an ester or a salt.
The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, pionate, picrate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001 to 50 mg/kg body weight daily and more usually 0.01 to 1 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the preferred dosage regimen set forth above.
The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
Injectable preparations, or example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents. For example, the compounds of the invention can be administered in combination with AZT, DDI, DDI or with glucosidase inhibitors, such as N-butyl-1-deoxynojirimycin or prodrugs thereof, for the prophylaxis and/or treatment of AIDS. When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.
The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scone thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

## Claims

1. A compound represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein:
R represents 2-quinolinylcarbonyl;
R′ represents hydrogen and radicals as defined for R3 or R′′SO2— wherein R′′ represents radicals as defined for R3;
R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-alkyl serine, aspartic acid, beta-cyano alanine and valine side chains;
R1′′ and R1′′ independently represent hydrogen and radicals as defined for R1, or one of R1′′ and R1′′, together with R1 and the carbon atoms to which R1, R1′′ and R1′′ are attached, represent a cycloalkyl radical;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, —NO2, —C≡N, CF3, —OR9, —SR9, wherein R9 represents hydrogen and alkyl radicals;
R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals, and thioalkyl, alkylthioalkyl and arythioalkyl radicals and the sulfone or sulfoxide thereof;
R4 and R5 independently represent hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof;
R6 represents hydrogen and alkyl radicals;
x represents 1 or 2;
t represents either 0, 1 or 2; and
Y represents O.

2. Compound of claim 1 represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein:
R represents 2-quinclinylcarbenyl;
R1 represents hydrogen and radicals as defined for R3;
R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2)thereof, islleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalnine, orithinine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-alkyl serine, aspartic acid, beta-cyano alanine and valine side chains;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, —NO2, —C≡N, CF3, —OR9, —SR9, wherein R9 represents hydrogne and alkyl radicals;
R3 represents alkyl, haloalkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof;
R4 and R5 independently represent hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof.

3. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 represents alkyl, alkynyl and alkenyl radicals, and amino acid side chains selected, from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, S-methyl cysteine and the sulfone and sulfoxide thereof, alanine, and allo-isoleucine.

4. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R1 represents methyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine, and allo-threonine side chains.

5. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula —OR9 and —SR9 wherein R9 represents hydrogen and alkyl radicals.

6. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R2 represents alkyl, cycloalkylalkyl and aralkyl radicals.

7. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R2 represents CH3SCH2CH2—, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

8. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 independently represents alkyl, haloalkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, and aralkyl radicals.

9. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 represents alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, radicals.

10. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 and R4 independently represent alkyl radicals.

11. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 represents isobutyl, n-propyl, isopropyl, n-butyl, isoamyl, cyclohexyl, cyclohexylmethyl, and benzyl radicals.

12. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 is an isobutyl, n-butyl or isoamyl radical and R4 is a tertiary-butyl radical.

13. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 is an isobutyl, n-butyl or isoamyl radical and R4 is a phenyl radical.

14. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R4 and R5 independently represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, and aralkyl radicals.

15. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R4 and R5 independently represent hydrogen, alkyl and aryl radicals.

16. Compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R4 and R5 independently represent hydrogen, methyl, ethyl, isopropyl, n-butyl, t-butyl, 1,1-dimethylpropyl, cyclohexyl and phenyl radicals.

17. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of claim 17.

19. Compound of claim 1 represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein:
R represents 2-quinolinylcarbonyl;
R′ represents hydrogen and radicals as defined for R3;
R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, —NO2, —C≡N, CF3, —OR9, —SR9, wherein R9 represents hydrogen and alkyl radicals;
R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof;
R4 and R5 independently represent hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof.

20. A pharmaceutical composition comprising a compound of claim 19 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of claim 20.

22. Compound of claim 1 represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein:
R represents 2-quinolinylcarbonyl;
R′ represents hydrogen and radicals as defined for R3;
R1 represents hydrogen, —CH2SO2NH2, —CH2CO2CH3, —CO2CH3, —CONH2, —CH2C(O)NHCH3, —C(CH3)2(SH), —C(CH3)2(SCH3), —C(CH3)2(S[O]CH3), —C(CH3)2(S[O]2CH3), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and methionine and the sulfoxide (SO) and sulfone (SO2) thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, aspartic acid, beta-cyano alanine and valine side chains;
R1′ and R1′′ independently represent hydrogen and radicals as defined for R1, or one of R1′ and R1′′, together with R1 and the carbon atoms to which R1, R1′ and R1′′ are attached, represent a cycloalkyl radical;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, —NO2, —C≡N, CF3, —OR9, —SR9, wherein R9 represents hydrogen and alkyl radicals;
R3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof;
R4 and R5 independently represent hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl radicals, and thioalkyl, alkylthioalkyl and arylthioalkyl radicals and the sulfone or sulfoxide thereof.

23. A pharmaceutical composition comprising a compound of claim 22 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of claim 23.

25. A compound of claim 1 which is:
N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide;
N1-[3-[[(1,1-dimethylethyl)amino]sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-[phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino)butanediamide;
N′-[3-[[phenylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide; or
N′-[3-[[cyclohexylaminolsulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide,
or a pharmaceutically acceptable salt thereof.